




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 471/10, 498/10, A61K 31/435, C07D 317/14 // (C07D 471/10, 235:00, 221:00) (C07D 498/10, 263:00, 221:00)	A1	(11) International Publication Number: WO 97/00872 (43) International Publication Date: 9 January 1997 (09.01.97)
(21) International Application Number: PCT/EP96/02554 (22) International Filing Date: 13 June 1996 (13.06.96) (30) Priority Data: 494,134 23 June 1995 (23.06.95) US (71) Applicant: F.HOFFMANN-LA ROCHE AG [CH/CH]; Gren- zacherstrasse 124, CH-4070 Basle (CH). (72) Inventors: BERGER, Jacob; 12135 Dawn Lane, Los Altos Hills, CA 94022 (US). CARTER, David, Scott; Apartment 207, 2536 Anacapa Drive, Costa Mesa, CA 92626 (US). FLIPPIN, Lee, Allen; 17659 Skyline Boulevard, Woodside, CA 94062 (US). WEINHARDT, Klaus, Kurt; 1042 Col- orado Avenue, Palo Alto, CA 94303 (US). (74) Agent: POPPE, Regina; Grenzacherstrasse 124, CH-4070 Basle (CH).		(81) Designated States: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: 1,3,8-TRIAZA- AND 3,8-DIAZA-1-OXASPIRO(4,5)DECANE DERIVATIVES**(57) Abstract**

Heterocyclic compounds of Formula (I) in which n is 2, 3, 4, 5 or 6; t is 1, 2, 3 or 4; u is 0 or 1 (provided that t is not 1 when u is 0); X is O or N(R⁴), in which R⁴ is hydro, (C₁₋₄)alkyl, or aryl; Y and Z are independently C(O), C(S) or CH₂ (provided that Y and Z are not both CH₂); R¹, R², and R³ are as defined in the specification; and their pharmaceutically acceptable salts and N-oxides, formulations containing them, their uses as therapeutic agents, and their synthesis. The compounds of this invention are selective 5-HT_{2C} receptor antagonists.



FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

1,3,8 Triaza- and 3,8-diaza-1-oxaspiro(4,5)decane derivatives

This application relates to a compound of Formula I:



I

5 in which:

n is 2, 3, 4, 5 or 6;

t is 1, 2, 3 or 4 and

u is 0 or 1 (provided that t is not 1 when u is 0);

X is O or N(R⁴), in which R⁴ is hydro, (C₁-4)alkyl or
10 aryl;

Y and Z are independently C(O), C(S) or CH₂ (provided that Y
and Z are not both CH₂);

each

R¹ is independently amino, aryloxy, aryl(C₁-4)alkyloxy,
15 arylsulfonyl, arylthio, carbamoyl, cyano, halo,

nitro, thiocarbamoyl, thioureido, ureido, a
group selected from (C₁-4)alkyl, (C₁-4)alkyloxy and
(C₁-4)alkylthio (optionally further substituted with
one to three halo atoms), a group selected from
20 -NHSO₂R⁵, -NHC(O)R⁵, -NHC(O)NHR⁵, -NHC(S)NHR⁵ and
-SO₂NHR⁵ (which R⁵ is (C₁-4)alkyl (optionally further

substituted with one to three halo atoms) or a group
selected from aryl, aryl(C₁-4)alkyl, heteroaryl and
heteroaryl(C₁-4)alkyl (optionally further substituted
25 with one to two radicals independently selected from
amino, carbamoyl, cyano, halo, nitro, a group
selected from (C₁-4)alkanoyl,


(C₁-4)alkylsulfonylamino, (C₁-4)alkanoylamino,
(C₁-4)alkyl and (C₁-4)alkyloxy, optionally further

30 substituted with one to three halo atoms, and a group

selected from aryl, arylsulfonyl, heteroaryl and heteroarylsulfonyl, optionally further substituted with one to two radicals independently selected from amino, cyano, halo, nitro and a group selected from (C₁₋₄)alkyl and (C₁₋₄)alkyloxy, optionally further substituted with one to three halo atoms}} or two adjacent R¹ substituents form ethylenedioxy, methylenedioxy or butadienylenes (which butadienylenes is optionally further substituted with one to two radicals selected from halo and (C₁₋₄)alkyloxy);

R² is hydroxy, halo, (C₁₋₄)alkyloxy or aryl(C₁₋₄)alkyloxy; and

R³ is hydro, (C₁₋₆)alkyl (optionally substituted with a group selected from -C(O)OH, -C(O)O(C₁₋₄)alkyl, -NHSO₂R⁵ and -NHC(O)R⁵, in which R⁵ is as defined above), hydroxyalkyl, phenyl(C₁₋₄)alkyl (optionally substituted with one or two radicals independently selected from amino, cyano, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, acetamido, methanesulfonamido, (C₁₋₄)alkyl, or (C₁₋₄)alkyloxy), or a group of Formula (a):



wherein n, t and R¹ are as defined above;

and the pharmaceutically acceptable salts and N-oxides thereof.

A second aspect of this invention is a pharmaceutical composition which contains a compound of Formula I in admixture with one or more suitable excipients.

A third aspect of this invention is the processes for preparing the above-identified compounds.

Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:

5 The term "hydro" means hydrogen.

 "Aryl", as in aryl, aryl(C₁₋₄)alkyl, aryl(C₁₋₄)alkyloxy, aryloxy, arylsulfonyl and arylthio means an organic radical derived from an aromatic hydrocarbon containing 6 to 14 carbon
10 atoms and includes monocyclic or condensed carbocyclic aromatic rings (e.g., phenyl, naphthyl, anthracenyl, phenanthrenyl, etc.) optionally substituted with one or more radicals.

15 "Alkyl", as in (C₁₋₆)alkyl, (C₁₋₆)alkyloxy and (C₁₋₄)-alkylthio, means a straight or branched saturated hydrocarbon radical having from one to the number of carbon atoms designated optionally substituted with one to three halo atoms (e.g., optionally substituted (C₁₋₄)alkylthio includes
20 methylthio, ethylthio, 2,2,2-trifluoroethylthio, etc.; optionally substituted (C₁₋₆)alkyl includes methyl, trifluoromethyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, etc.; and optionally substituted (C₁₋₆)alkyloxy includes methoxy, difluoromethoxy, trifluoromethoxy, ethoxy,
25 2,2,2-trifluoroethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, etc.).

 "Hydroxyalkyl" means a straight or branched monovalent hydrocarbon radical of two to four carbons substituted with
30 one or two hydroxy groups, provided that: (1) the bonding carbon is unsubstituted with hydroxy, and (2) if two hydroxy groups are present, they are not both on the same carbon atom. Examples include 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxy-
35 butyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and

2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl, and 1-(hydroxymethyl)-2-hydroxyethyl, and 2-(hydroxymethyl)-3-hydroxypropyl.

5 "Alkanoyl" means the radical $-C(O)R$, in which R is H or alkyl as the term is defined above (e.g., the term (C_{1-4}) -alkanoyl includes formyl, acetyl, propionyl, and butyryl).

"Carbamoyl" means aminocarbonyl.

10

"Halo" means fluoro, chloro, bromo, or iodo.

"Heteroaryl", as in heteroaryl, heteroaryl (C_{1-4}) alkyl, heteroaryloxy, heteroaryl (C_{1-4}) alkyloxy and
15 heteroarylsulfonyl, means an organic radical derived from an aromatic hydrocarbon containing 5 to 14 atoms, 1 to 5 of which are hetero atoms chosen from N, O, or S, and includes monocyclic, condensed heterocyclic and condensed carbocyclic and heterocyclic aromatic rings (e.g., thienyl, furyl,
20 pyrrolyl, pyrimidinyl, isoxazolyl, oxazolyl, indolyl, benzo[b]thienyl, isobenzofuranyl, purinyl, isoquinolyl, pterdinyl, perimidinyl, imidazolyl, pyridyl, pyrazolyl, pyrazinyl, etc.) optionally substituted with one to two radicals independently selected from halo and cyano.

25

"Sulfamoyl" means the radical aminosulfonyl.

"Thiocarbamoyl" means the radical $-C(S)NH_2$.

30

"Thioureido" means the radical $-NHC(S)NH_2$.

"Leaving group" has the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or group displaceable under alkylating conditions, and includes halogen
35 and alkane- or arenesulfonyloxy, such as mesyloxy, ethane-

sulfonyloxy, benzenesulfonyloxy and tosyloxy, and thienyloxy, dihalophosphinoyloxy, tetrahalophosphaoxy, and the like.

"Animal" includes humans, non-human mammals, e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, and deer, and non-mammals, e.g., birds and the like.

"Disease" specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition which may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the "side effects" of such therapy.

"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, the phrase "optionally further substituted with one to three halo atoms" means that the group referred to may or may not be substituted in order to fall within the scope of the invention.

"Protective group" has the meaning conventionally associated with it in synthetic organic chemistry, i.e., a group which selectively blocks one reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site and which can be readily removed after the selective reaction is completed.

30

"Protecting agent" means an agent which will react with a multifunctional compound and create a protective group at reactive nitrogen atoms.

"Protected" in reference to a compound or a group means a derivative of compound or group in which a reactive site or sites are blocked with protective groups.

5 "Deprotecting" refers to removing any protective groups present after the selective reaction has been carried out.

"Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally
10 safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.

"Pharmaceutically acceptable salts" means salts which are
15 pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrobromic acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid and the like; or with organic
20 acids such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, *p*-chlorobenzene-sulfonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, 1,2-ethanedisulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic
25 acid, hexanoic acid, heptanoic acid, *o*-(4-hydroxybenzoyl)benzoic acid, 2-hydroxyethanesulfonic acid, hydroxynaphthoic acid, lactic acid, lauryl sulfuric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-
30 1-carboxylic acid, 4,4'-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), muconic acid, 2-naphthalenesulfonic acid, oxalic acid, 3-phenylpropionic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tartaric acid, tertiary butylacetic acid, *p*-toluenesulfonic acid,
35 trimethylacetic acid and the like.

Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases. Acceptable inorganic bases include aluminum hydroxide, calcium
5 hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide. Acceptable organic bases include diethanolamine, ethanolamine, *N*-methylglucamine, triethanolamine, tromethamine and the like.

10 "N-Oxide", when referring to a compound of Formula I, means such compound in which nitrogens are in an oxidized state, i.e., $O \leftarrow N$. The *N*-oxides of compounds of Formula I can be prepared by methods known to those of ordinary skill in the art.

15 "Therapeutically effective amount" means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.

20 The term "q.s." means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).

"Treating" or "treatment" of a disease includes:

- 25
- (1) preventing the disease from occurring in an animal which may be predisposed to the disease but does not yet experience or display symptoms of the disease,
 - (2) inhibiting the disease, i.e., arresting its development,
 - 30 or
 - (3) relieving the disease, i.e., causing regression of the disease.

For the purposes of this application the term
35 " α -position" in reference to a compound of Formula I, 3 or 6-17 means that position on the phenyl group of the benzoyl

moiety which is adjacent to the position at which the carbonyl carbon, or a protected derivative thereof, is attached. A reference to " β -, γ - or δ -position" means that position on the phenyl group as it would traditionally relate to the

5 a-position.


"Adjacent" as in the term "two adjacent R^1 substituents form ethylenedioxy, methylenedioxy or butadienylene" means that two R^1 radicals are at adjacent positions on the phenyl

10 ring and together form a bivalent radical (e.g., α,β -butadienylene, β,γ -butadienylene, γ,δ -butadienylene, β,γ -methylenedioxy, α,β -ethylenedioxy, etc.).

The compounds of Formula I are named by AUTONOM Version

15 1.0 by Beilstein-Institut and Springer-Verlag Berlin Heidelberg, a fully automatic computerized system for assigning IUPAC systematic nomenclature directly from the structural diagrams of organic compounds. For example, a compound of the following formula:

20



is named *N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-pentanoyl]-2,4-dimethoxyphenyl)benzenesulfonamide when n is 4,

25 t is 2, u is 1, Z is $C(O)$, R^1 is phenylsulfonylamino and methoxy at the β - and γ -positions, respectively, R^2 is methoxy and R^3 is hydro;

is named 8-[5-(2,3-ethylenedioxyphenyl)-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione when n is 4, t is 2, u is 0,

30 Z is $C(O)$, R^1 is α,β -ethylenedioxy and R^3 is hydro; and

is named *N*-(2-{8-[4-(2,4-dimethoxyphenyl)-4-oxobutyl]-1,3,8-triaza-2,4-dioxo-spiro[4.5]dec-3-yl}ethyl)methanesulfonamide

when n is 3, t is 1, u is 1, R¹ is methoxy at the γ -position, R² is methoxy and R³ is 2-(methylsulfonylamino)ethyl.

Certain compounds of Formula I are preferred. For example, preferred compounds of Formula I are those in which n is 3, 4, 5 or 6; u is 0; X is NH; Y is C(O); Z is C(O) or C(S); two adjacent R¹ radicals form α,β -ethylenedioxy; a third R¹ radical, when present, is amino, phenyl, phenoxy, halo, nitro, ureido, thioureido, (C₁₋₄)alkyloxy, a group selected from -NHSO₂R⁵, -NHC(O)R⁵, -NHC(O)NHR⁵ and -NHC(S)NHR⁵ (which R⁵ is (C₁₋₄)alkyl or a group selected from phenyl, naphthyl and thienyl (optionally further substituted with one to two radicals independently selected from amino, carbamoyl, cyano, halo, nitro, a group selected from (C₁₋₄)alkanoyl, (C₁₋₄)alkylsulfonylamino, (C₁₋₄)alkanoylamino, (C₁₋₄)alkyl and (C₁₋₄)alkyloxy, optionally further substituted with one to three halo atoms, and a group selected from aryl, arylsulfonyl, heteroaryl and heteroarylsulfonyl, optionally further substituted with one to two radicals independently selected from amino, cyano, halo, nitro and a group selected from (C₁₋₄)alkyl and (C₁₋₄)alkyloxy, optionally further substituted with one to three halo atoms)); and R³ is hydro, (C₁₋₆)alkyl (optionally substituted with a group selected from -C(O)OH, -C(O)O(C₁₋₄)alkyl, -NHSO₂R⁵ and -NHC(O)R⁵, in which R⁵ is as defined above), hydroxyalkyl, or phenyl(C₁₋₄)alkyl (optionally substituted with one or two radicals independently selected from amino, cyano, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, acetamido, methanesulfonamido, (C₁₋₄)alkyl, or (C₁₋₄)alkyloxy).

30

Other preferred compounds of Formula I are those in which n is 3, 4, 5 or 6; X is NH; Y is C(O); Z is C(O) or C(S); u is 1; t is 1, 2 or 3; R¹ is amino, phenyl, phenoxy, halo, nitro, ureido, thioureido, (C₁₋₄)alkyloxy, a group selected from -NHSO₂R⁵, -NHC(O)R⁵, -NHC(O)NHR⁵ and -NHC(S)NHR⁵ (which R⁵ is (C₁₋₄)alkyl or a group selected from phenyl, naphthyl, thienyl

35

(optionally further substituted with one to two radicals independently selected from amino, carbamoyl, cyano, halo, nitro, a group selected from (C₁₋₄)alkanoyl, (C₁₋₄)alkyl-sulfonylamino, (C₁₋₄)alkanoylamino, (C₁₋₄)alkyl and (C₁₋₄)-
5 alkyloxy, optionally further substituted with one to three halo atoms, and a group selected from aryl, arylsulfonyl, heteroaryl and heteroarylsulfonyl, optionally further substituted with one to two radicals independently selected from amino, cyano, halo, nitro and a group selected from (C₁₋₄)alkyl and (C₁₋₄)alkyloxy, optionally further substituted
10 with one to three halo atoms)} or with an adjacent R¹ radical form butadienylene (which butadienylene is optionally further substituted with one to two radicals selected from halo and (C₁₋₄)alkyloxy); R² is (C₁₋₄)alkyloxy; and R³ is hydro, (C₁₋₄)alkyl (optionally substituted with a group selected from
15 -C(O)OH, -C(O)O(C₁₋₄)alkyl, -NHSO₂R⁵ and -NHC(O)R⁵, in which R⁵ is as defined above), hydroxyalkyl, or phenyl(C₁₋₄)alkyl (optionally substituted with one or two radicals independently selected from amino, cyano, halo, hydroxy, nitro,
20 trifluoromethyl, trifluoromethoxy, acetamido, methanesulfonamido, (C₁₋₄)alkyl, or (C₁₋₄)alkyloxy).

Particularly preferred are those compounds of Formula I in which n is 4, 5 or 6; X is NH; Y is C(O); Z is C(O) or
25 C(S); u is 1; t is 1, 2, or 3; an R¹ radical is attached at the β- and/or γ-positions, which R¹ radical when attached at the β-position is amino, phenoxy, chloro, nitro, (C₁₋₄)alkyloxy or -NHSO₂R⁵ (which R⁵ is a group selected from phenyl or thienyl (optionally further substituted with one to
30 two radicals independently selected from amino, carbamoyl, cyano, halo, nitro, a group selected from (C₁₋₄)alkanoyl, (C₁₋₄)alkylsulfonylamino, (C₁₋₄)alkanoylamino, (C₁₋₄)alkyl and (C₁₋₄)alkyloxy, optionally further substituted with one to three halo atoms, and a group selected from aryl,
35 arylsulfonyl, heteroaryl and heteroarylsulfonyl, optionally further substituted with one to two radicals independently

selected from amino, cyano, halo, nitro and a group selected from (C₁₋₄)alkyl and (C₁₋₄)alkyloxy, optionally further substituted with one to three halo atoms)} and when attached at the γ -position is chloro, (C₁₋₄)alkyloxy or amino; R² is methoxy; and R³ is hydro, (C₁₋₆)alkyl (optionally substituted with a group selected from -C(O)OH, -C(O)O(C₁₋₄)alkyl, -NHSO₂R⁵ and -NHC(O)R⁵, in which R⁵ is as defined above), hydroxyalkyl, or phenyl(C₁₋₄)alkyl (optionally substituted with one or two radicals independently selected from amino, cyano, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, acetamido, methanesulfonamido, (C₁₋₄)alkyl, or (C₁₋₄)alkyloxy).

Most preferred are those compounds of Formula I in which n is 4; X is NH; Y is C(O); Z is C(O); u is 1; t is 2 or 3; a first R¹ radical is attached at the β -position and is phenylsulfonylamino (optionally further substituted with amino, carbamoyl, cyano, chloro, fluoro, nitro or a group selected from (C₁₋₄)alkanoyl, (C₁₋₄)alkylsulfonylamino, (C₁₋₄)alkanoylamino, (C₁₋₄)alkyl and (C₁₋₄)alkyloxy, optionally further substituted with one to three fluoro atoms), a second R¹ radical is attached at the γ -position and is methoxy, the third R¹ radical if present is attached at the α -position and is methoxy; R² is methoxy; and R³ is hydro, (C₁₋₆)alkyl, hydroxyalkyl, or phenyl(C₁₋₄)alkyl (where the phenyl is optionally substituted halo, hydroxy, (C₁₋₄)alkyloxy, or trifluoromethyl).

The compounds of this invention are selective 5-HT_{2C} receptor antagonists. Affinities for the 5-HT_{2C} receptor were measured by a cloned rat 5-HT_{2C} receptor binding assay (for details see Example 30, *infra*). Antagonist properties were determined in NIH3T3 cells, transfected with cloned rat 5-HT_{2C} receptor, by measuring the propensity of the compounds to inhibit 5-HT induced/5-HT_{2C} mediated increases in cellular metabolic activity (for further details see Example 31,

infra.). Accordingly, the compounds of this invention are useful for treating diseases which can be ameliorated by blocking 5-HT_{2C} receptors. For example, clinical and experimental evidence support a therapeutic role for 5-HT_{2C} receptor antagonists in treating anxiety. The 5-HT_{2C} receptor agonist 1-(3-chlorophenyl)-piperazine [mCPP] when administered to human volunteers causes anxiety (see Charney et al. (1987), *Psychopharmacology*, 92, 14-24). mCPP also produces anxiogenic effects in rat, social interaction (SI) and elevated X-maze models of anxiety, which effects are blocked by non-selective 5-HT_{2C/2A} receptor antagonists but not by selective 5-HT_{2A} receptor antagonists (see Kennett et al. (1989), *Eur. J. Pharmacol.*, 164, 445-454 and Kennett (1993), *supra.*). In addition, non-selective 5-HT_{2C/2A} receptor antagonists by themselves produce anxiolytic effects in the SI and Geller Seifter conflict tests, while selective 5-HT_{2A} receptor antagonists do not share this property.

Furthermore, mCPP when administered to panic disorder patients or obsessive compulsive disorder patients increases levels of panic and/or anxiety (see Charney et al. (1987), *supra.*, and Zohar et al. (1987), *Arch. Gen. Psychiat.*, 44, 946-951). Thus, current evidence support the application of selective 5-HT_{2C} receptor antagonists for treating generalized anxiety disorder, panic disorder and obsessive compulsive disorder.

Anxiolytic activity can be determined experimentally by the art-recognized Crawley and Goodwin two-compartment exploratory model (e.g., see Kilfoil et al. (1989), *Neuropharmacology*, 28(9), 901-905). In brief, the method measures the extent a compound affects the natural anxiety of mice in a novel, brightly lighted area (for further details see Example 32, *infra.*).

Clinical and experimental evidence support a therapeutic role for selective 5-HT_{2C} receptor antagonists in treating chemical dependency. The 5-HT_{2C} receptor agonist mCPP induces a craving for alcohol in abstaining alcoholics (see Benkelfat et al. (1991), *Arch. Gen. Psychiat.*, 48, 383). In contrast, the non-selective 5-HT_{2C/2A} receptor antagonist ritanserin reduces alcohol preference in rats (see Meert et al., (1991), *Drug Development Res.* 24, 235-249), while the selective 5-HT_{2A} receptor antagonist ketanserin has no affect on preference for alcohol (see Kennett et al., (1992), *J. Psychopharmacol.*, Abstr. A26). Ritanserin also reduces both cocaine and fentanyl preference in rat models of addiction (see Meert et al. (1991), *Drug Development Res.* 25, 39-53 and Meert et al., (1991), *Drug Development Res.* 25, 55-66). Clinical studies show that ritanserin decreases alcohol intake in chronic alcoholics (see Monti et al. (1991), *Lancet.* 337, 60) and is useful in patients withdrawing from other drugs of abuse (see Sadzot et al. (1989), *Psychopharmacology*, 98, 495-499). Thus, current evidence support the application of selective 5-HT_{2C} receptor antagonists for treating alcoholism and addiction to other drugs of abuse.

Ameliorating effects of compounds during withdrawal from drugs of abuse can be determined experimentally by the mouse, withdrawal anxiety test, an accepted assay (e.g., see Carboni et al. (1988), *Eur. J. Pharmacol.*, 151, 159-160). This procedure utilizes the exploratory model described above to measure the extent a compound ameliorates the symptoms of withdrawal that occur after chronically treating with an addictive substance and then abruptly ceasing the treatments (for further details see Example 33, *infra.*).

Clinical evidence support a therapeutic role for selective 5-HT_{2C} receptor antagonists in treating depression. For example, non-selective 5-HT_{2C/2A} receptor antagonists show clinical efficacy in treating depression (see Murphy (1978),

Brit. J. Pharmacol., 5, 81S-85S; Klieser et al. (1988), *Pharmacopsychiat.*, 21, 391-393; and Camara (1991), *Biol. Psychiat.*, 29, 201A). Furthermore, experimental results suggest that the mechanism by which conventional antidepressant drugs exert their therapeutic efficacy is through adaptive changes in the serotonergic system (see Anderson (1983), *Life Sci*, 32, 1791-1801). For example, chronic treatment with monamine oxidase inhibitors reduce mCPP-induced/5-HT_{2C} mediated functional responses in a variety of paradigms. Similar effects are exhibited by selective 5-HT reuptake inhibitors. These findings suggest that treatments which enhance extraneuronal 5-HT levels desensitize 5-HT_{2C} receptor function which in turn causes, or contributes to, antidepressant activity (see Kennett (1993), *supra.*).

Clinical evidence support a therapeutic role for selective 5-HT_{2C} receptor antagonists in treating migraine. The 5-HT_{2C} receptor agonist mCPP when administered to human volunteers causes migraine-like headaches. In contrast, non-selective 5-HT_{2C/2A} receptor antagonists are clinically effective antimigraine agents, while the selective 5-HT_{2A} receptor antagonist ketanserin is not (see Winther (1985), *Cephalalgia*, 5, 402-403). Furthermore, experimental results suggest that the clinical efficacy of chronic administration of 5-HT reuptake inhibitors as migraine prophylactics is due to desensitization of 5-HT_{2C} receptors (see Kennett (1993), *supra.*, and the above discussion on 5-HT_{2C} receptor desensitization and depression).

Clinical evidence support a therapeutic role for 5-HT_{2C} receptor antagonists in treating sleep disorders. The 5-HT_{2C} receptor agonist mCPP when administered to human volunteers reduces total sleep time, sleep efficiency, slow wave sleep (SWS) and rapid eye movement sleep (see Lawlor et al. (1991), *Biol. Psychiat.*, 29, 281-286). In contrast, the non-selective 5-HT_{2C/2A} receptor antagonist ritanserin increases SWS,

reduces sleep onset latency and improves subjective sleep quality in healthy volunteers (see Idzikowski et al. (1986), *Brain Res.*, 378, 164-168; Idzikowski et al. (1987), *Psychopharmacology*, 93, 416-420; Declerck et al. (1987), *Curr. Therap. Res.*, 41, 427-432; and Adam et al. (1989), *Psychopharmacology*, 99, 219-221). Thus, given the opposing effects of 5-HT_{2C} receptor stimulation and 5-HT_{2C} receptor antagonism, selective 5-HT_{2C} receptor antagonists could be of particular therapeutic value in treating sleep disorder (see Kennett (1993), *supra.*).

Clinical evidence support a therapeutic role for 5-HT_{2C} receptor antagonists in feeding disorders. Non-specific 5-HT_{2C/2A} receptor antagonists are shown to produce increased appetite and weight gain. Thus, there is some clinical evidence to support the application of selective 5-HT_{2C} receptor antagonists for the treatment of anorexia nervosa.

Experimental evidence support a therapeutic role for 5-HT_{2C} receptor antagonists in treating priapism. mCPP produces penile erections in rats, an effect that is blocked by non-selective 5-HT_{2C/2A} receptor antagonists but not by selective 5-HT_{2A} receptor antagonists (see Hoyer (1989), In: Fozard J. (ed.) *Peripheral actions of 5-HT*, Oxford University Press, Oxford, 72-99).

In general, compounds of Formula I will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with another compound of Formula I or with another therapeutic agent. A therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. Therapeutically effective amounts of compounds of Formula I may range from 0.1 micrograms per kilogram body weight ($\mu\text{g/kg}$) per day to 1

milligram per kilogram body weight (mg/kg) per day, typically 1 µg/kg/day to 10 µg/kg/day. Therefore, a therapeutically effective amount for a 80 kg human may range from 8 µg/day to 800 mg/day, typically 80 µg/day to 0.8 mg/day.

5

One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of a compound of Formula I for a given disease.

10

In general, compounds of Formula I will be administered as pharmaceutical compositions by one of the following routes: oral, systemic (e.g., transdermal, intranasal or by
15 suppository) or parenteral (e.g., intramuscular, intravenous or subcutaneous). Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate composition and are comprised of, in
20 general, a compound of Formula I in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of Formula I. Such excipient may be any solid, liquid, semisolid
25 or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.

Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt,
30 rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, and the like. Liquid and semisolid excipients may be selected from water, ethanol, glycerol, propylene glycol and various oils, including those of petroleum, animal, vegetable
35 or synthetic origin (e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.). Preferred liquid carriers,

particularly for injectable solutions, include water, saline, aqueous dextrose and glycols.


Compressed gases may be used to disperse the compound of
5 Formula I in aerosol form. Inert gases suitable for this
purpose are nitrogen, carbon dioxide, nitrous oxide, etc.
Other suitable pharmaceutical carriers and their formulations
are described in A.R. Alfonso Remington's *Pharmaceutical
Sciences* 1985, 17th ed. Easton, Pa.: Mack Publishing Company.

10

The amount of a compound of Formula I in the composition
may vary widely depending upon the type of formulation, size
of a unit dosage, kind of excipients and other factors known
to those of skill in the art of pharmaceutical sciences. In
15 general, the final composition will comprise from 0.000001%w
to 10.0%w of the compound of Formula I, preferably 0.00001%w
to 1.0%w, with the remainder being the excipient or
excipients.

20 Preferably the pharmaceutical composition is administered
in a single unit dosage form for continuous treatment or in a
single unit dosage form ad libitum when relief of symptoms is
specifically required. Representative pharmaceutical
formulations containing a compound of Formula I are described
25 in Example 29.

The compounds of Formula I can be prepared by the process
depicted in Scheme 1.

Scheme 1

- 5 in which L is a leaving group, R⁶ and R⁷ form oxo or a carbonyl protective group and each n, t, u, X, Y, Z, R¹, R² and R³ are as defined above with respect to Formula I.


Compounds of Formula I can be prepared by alkylating an
 10 appropriate heterocyclic spiro[4.5]decane (Formula 2),
 typically a salt thereof (e.g., hydrochloride, trifluoro-
 acetate, hydrobromide, sulfate, etc.), with an appropriate
 1-phenyl-1-(C₃₋₇)alkanone or protected derivative thereof
 (Formula 3), and then deprotecting when necessary. The
 15 alkylation is carried out with 0.8 to 2 molar equivalents,
 typically 1 to 1.5 and preferably approximately 1.3 molar
 equivalents of the compound of Formula 2, in a suitable inert
 organic solvent (e.g., *N,N*-dimethylformamide (DMF), 1-methyl-
 2-pyrrolidione, *N,N*-dimethylacetamide, dimethylsulfoxide,
 20 sulfolane, 1,1,3,3-tetramethylurea, any appropriate mixture of
 suitable solvents, etc., preferably DMF) with a suitable base
 present, typically a nitrogen base (e.g., triethylamine,
N,N-diisopropylethylamine, etc.) or a carbonate salt base

(e.g., potassium carbonate, sodium carbonate, cesium carbonate, etc.) and preferably triethylamine, and optionally an iodide salt present (e.g., sodium iodide, lithium iodide, tetraalkylammonium iodides such as tetramethylammonium iodide and the like, etc., preferably sodium iodide) at 40 to 130°C, typically at 70 to 115°C and preferably at approximately 110°C, requiring 4 to 24 hours (for further details see Example 23, *infra.*). Compounds of Formula I in which R³ is a group of Formula (a) can be prepared by proceeding as described above with respect to Scheme 1, but substituting approximately 2 molar equivalents, of the compound of Formula 3.

Deprotection when R⁶ and R⁷ comprise a carbonyl protective group can be effected by any means which removes the protective group and gives the desired product in reasonable yield. A detailed description of the techniques applicable to protective groups and their removal can be found in T.W. Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, Inc. 1981. For example, a convenient method of deprotecting when the protective group is ethylenedioxy is carried out by acid-catalyzed exchange dioxolanation, by acid-catalyzed hydrolysis or oxidation. A preferred method of cleaving a ethylenedioxy protective group is by acid-catalyzed hydrolysis and is carried out with an appropriate acid (e.g., hydrochloric acid, oxalic acid, sulfuric acid, etc., preferably hydrochloric acid) in a suitable inert organic solvent, typically an aqueous alcohol (e.g., methanol, ethanol, 2-ethoxyethanol, any appropriate mixture of suitable alcohols, etc.) and preferably methanol or a dilute aqueous acid alone or in combination with a suitable solvent (e.g., THF, dioxane, any appropriate mixture of suitable solvents, etc.), typically at 20 to 85°C and preferably at approximately 65°C, requiring 0.2 to 2 hours (for further details see Example 24, *infra.*).

Alternatively, compounds of Formula I can be prepared by the process depicted in Scheme 2.

Scheme 2




in which L is a leaving group and each n, t, u, X, Y, Z, R¹, R² and R³ are as defined above with respect to Formula I.

10

The compounds of Formula I can be prepared by acylating an appropriately substituted benzene derivative (Formula 4) with an activated α -spiro[4.5]dec-8-yl-1-(C₃₋₇)alkanone (Formula 5). The acylation is carried out in the presence of a Lewis acid (e.g., aluminum chloride (AlCl₃), boron trifluoride, hydrogen fluoride, phosphoric acid, etc., preferably AlCl₃) in a suitable solvent (e.g., ethylene dichloride (EDC), methylene chloride, carbon disulfide, any appropriate mixture of suitable solvent, etc., preferably EDC) typically at 0 to 80°C and preferably at approximately 25°C, requiring 12 to 48 hours.

Alternatively, compounds of Formula I in which X is NH, Y is C(O), Z is C(O) and R³ is hydro can be prepared by the process depicted in the following Scheme 3.

Scheme 3

in which R⁶ and R⁷ form a carbonyl protective group and each n, t, u, R¹ and R² are as defined above with respect to Formula I.


Compounds of Formula I in which X is NH, Y is C(O), Z is C(O) and R³ is hydro (Formula 6) can be prepared by alkylating 4-piperidone with a compound of Formula 3 to give a corresponding 1-(ω-phenyl(C₁₋₇)alkyl)-4-piperidone (Formula 7) and then reacting the compound of Formula 7 with an excess, preferably approximately 3 molar equivalents, of a cyanide salt (e.g., potassium cyanide, sodium cyanide, etc.) and an excess, preferably approximately 5 molar equivalents, of ammonium carbonate and deprotecting. The alkylation is carried out by proceeding as described above with respect to Scheme 1, but substituting the 4-piperidone for the compound of Formula 2. The reaction with the potassium cyanide and ammonium carbonate is carried out in a suitable solvent (e.g., methanol, ethanol-water, any appropriate mixture of

suitable solvents, etc.) typically at 20 to 100°C and preferably at approximately 65°C, requiring 2 to 8 hours. The deprotection is carried out by proceeding as described above with respect to *Scheme 1*.

5

Alternatively, compounds of Formula I in which X is O, Y is C(O), Z is C(O) and R³ is hydro can be prepared by the process depicted in the following *Scheme 4*.

10


Scheme 4

in which R⁶ and R⁷ form oxo or a carbonyl protective group and each n, t, u, R¹ and R² are as defined above with respect to Formula I.

Compounds of Formula I in which X is O, Y is C(O), Z is C(O) and R³ is hydro (Formula 8) can be prepared by reacting a compound of Formula 7 with a slight excess, preferably approximately 1.4 molar equivalents, of a cyanide salt (e.g., potassium cyanide, sodium cyanide, etc.) and a slight excess, preferably approximately 1.1 molar equivalents, of sodium bisulfate to give a corresponding 4-hydroxy-1-(ω-phenyl(C₃₋₇)alkyl)-4-piperidinecarbonitrile (Formula 9)

and then reacting the compound of Formula 9 with chlorosulfonyl isocyanate and deprotecting when necessary. The reaction with the cyanide salt and sodium bisulfate is carried out in a suitable solvent (e.g., water, alcohol-water, 5 acetonitrile, any appropriate mixture of suitable solvents, etc., preferably water) typically at 10 to 100°C and preferably at approximately 25°C, requiring 0.2 to 8 hours. The reaction with the isocyanate is carried out in a suitable solvent (e.g., toluene, dioxane, any appropriate mixture of 10 suitable solvents, etc., preferably toluene) typically at reflux. The deprotection is carried out by proceeding as described above with respect to *Scheme 1*.

Alternatively, compounds of Formula I in which X is O, Y 15 is CH₂ and Z is C(O) or C(S) can be prepared by the process depicted in the following *Scheme 5*.

Scheme 5

5

in which R^6 and R^7 form oxo or a carbonyl protective group, R^9 is O or S and each n , t , u , R^1 , R^2 and R^3 are as defined above with respect to Formula I.

- 10 Compounds of Formula I in which X is O, Y is CH_2 and Z is C(O) or C(S) (Formula 10) can be prepared by reacting a compound of Formula 7 with trimethylsulfoxonium iodide to give a corresponding ω -(6-aza-1-oxa-spiro[2.3]oct-6-yl)-1-phenyl-1-(C_3 -7)alkanone (Formula 12), aminating the compound of
- 15 Formula 12 with an amine of the formula NH_2R^3 to give a corresponding ω -(4-aminomethyl-4-hydroxypiperidin-1-yl)-1-phenyl-1-(C_3 -7)alkanone (Formula 11) and then reacting the compound of Formula 11 with 1,1'-carbonyldiimidazole or

1,1'-thiocarbonyldiimidazole, respectively, and deprotecting when necessary. The reaction with the trimethylsulfoxonium iodide is carried out in the presence of a strong base (e.g., sodium hydride, potassium hydride, *tert*-butyllithium, sodium *tert*-butoxide, etc., preferably sodium hydride), typically under an inert atmosphere (e.g., argon, nitrogen, etc.), in a suitable solvent (e.g., DMSO, sulfolane, etc., preferably DMSO), typically at 20 to 60°C and preferably at approximately 50°C and requires 0.5 to 2 hours.

10


The amination is carried out in a suitable solvent (e.g., 1-methylpyrrolidone, dioxane, THF, etc., preferably THF), typically at 50 to 120°C and preferably at approximately 100°C and requires 16 to 24 hours. The reaction with the diimidazole is carried out in a suitable solvent (e.g., DMF, THF, dioxane, any appropriate mixture of suitable solvents, etc., preferably THF) typically at 40 to 120°C and preferably at 80 to 100°C, requiring 3 to 12 hours. The deprotection is carried out by proceeding as described above with respect to *Scheme 1*.

15

Alternatively, compounds of Formula I in which X is NH, Y is C(S) and Z is C(O) or C(S) can be prepared by the process depicted in the following *Scheme 6*.

20

25

Scheme 6


5

in which R^6 and R^7 form a carbonyl protective group, R^9 is O or S and each n , t , u , R^1 , R^2 and R^3 are as defined above with respect to Formula I.

- 10 Compounds of Formula I in which X is NH, Y is C(S) and Z is C(O) or C(S) (Formula 13) can be prepared by reacting a compound of Formula 7 with an excess, preferably approximately 2 molar equivalents of a cyanide salt (e.g., potassium cyanide, sodium cyanide, etc.) and an excess of an ammonium
- 15 salt (e.g., ammonium hydroxide, ammonium chloride, any appropriate mixture of ammonium salts, etc.), preferably approximately 2.5 molar equivalents each of ammonium chloride and ammonium hydroxide, to give a corresponding 4-amino-1-(ω-phenyl(C₃₋₇)alkyl)-piperidine-4-carbonitrile (Formula 14) and
- 20 then reacting the compound of Formula 14 with carbon oxysulfide or carbon disulfide, respectively, and deprotecting when necessary. The reaction with the cyanide salt and ammonium salt is carried out in a suitable solvent, typically

an aqueous alcohol (e.g., methanol, ethanol, 2-ethoxyethanol, any appropriate mixture of suitable alcohols, etc.) and preferably methanol, at 0 to 70°C, typically at 25 to 50°C and preferably at approximately 50°C, requiring 2 to 16 hours (for
 5 further details see Example 20, *infra.*). The reaction with the carbon oxysulfide or carbon disulfide can be carried out in the same solvent system and essentially under the same reaction conditions as those describe above. Alternatively,
 10 *Scheme 1* can be carried out with the carbon oxysulfide or carbon disulfide present from the beginning and heating at 40 to 50°C for 4 to 24 hours. The deprotection is carried out by proceeding as described above with respect to *Scheme 1*.

Alternatively, compounds of Formula I in which X is NH, Y
 15 is C(O) and Z is C(O) or C(S) can be prepared by the process depicted in the following *Scheme 7*.

Scheme 7

in which R⁶ and R⁷ form oxo or a carbonyl protective group, R⁹ is O or S and each n, t, u, R¹, R², R³ and R⁴ are as defined above with respect to Formula I.

5 Compounds of Formula I in which X is NH, Y is C(O) and Z is C(O) or C(S) (Formula 15) can be prepared by hydrolyzing a compound of Formula 14 to give a corresponding 4-amino-1-(ω-phenyl(C₁₋₇)alkyl)-4-piperidinecarboxamide (Formula 16) and then reacting the compound of Formula 16 with
10 1,1'-carbonyldiimidazole or 1,1'-thiocarbonyldiimidazole, respectively, and deprotecting when necessary. The hydrolysis can be effected with an aqueous acid (e.g., sulfuric acid, hydrochloric acid, etc.) typically at 20 to 120°C and preferably at approximately 100°C and requires 5 minutes to 2
15 hours (for further details see Example 21, *infra.*) or a base (e.g., potassium hydroxide or the like) at 20 to 80°C. If R⁶ and R⁷ form an acid-labile carbonyl protective group, the protective group generally will be removed with acid hydrolyzation. The reaction with the diimidazole is carried
20 out in a suitable solvent (e.g., DMF, THF, dioxane, any appropriate mixture of suitable solvents, etc., preferably DMF) typically at 15 to 75°C and preferably at approximately 55°C, requiring 2 to 12 hours (for further details see Example 22, *infra.*). The deprotection is carried out by proceeding as
25 described above with respect to *Scheme 1*.

Additional Processes for Preparing Compounds of Formula I:

Compounds of Formula I in which R¹ is amino can be prepared by reducing a compound of Formula I in which R¹ is
30 nitro. The reduction can be carried out with a suitable chemical reducing agent or by catalytic hydrogenation. For example, the reduction is conveniently carried out by hydrogenating in the presence of a suitable catalyst (e.g., 5 or 10% Pd/C, palladium hydroxide, platinum oxide, palladium, palladium oxide, nickel, palladium acetate, etc., preferably
35 10% Pd/C) in a suitable solvent (e.g., THF, DMF, methanol,

ethyl acetate, ethanol, acetic acid, any appropriate mixture of suitable solvents, etc.) at 20 to 40°C, typically at 20 to 30°C and preferably at approximately 25°C, and 15 to 70 psi, typically at 15 to 30 psi and preferably at approximately 15 psi, and requires 0.5 to 24 hours (for further details see Example 25, infra.).

Compounds of Formula I in which R¹ is -NHC(S)NHR⁵, in which R⁵ is as defined above with respect to Formula I, can be prepared by reacting a compound of Formula I in which R¹ is amino with an appropriate isothiocyanate of the formula R⁵NC(S). The reaction is carried out in a suitable solvent (e.g., toluene, *N*-methyl-2-pyrrolidinone, DMF, 1,1,3,3-tetramethylurea, THF, dioxane, any appropriate mixture of suitable solvents, etc., preferably toluene or *N*-methyl-2-pyrrolidinone) at -10 to 70°C, typically at 15 to 40°C and preferably at approximately 25°C, requiring 10 minutes to 8 hours (for further details see Example 26, infra.). Proceeding similarly, but substituting for the isothiocyanate an appropriate isocyanate of the formula R⁵NC(O) compounds of Formula I in which R¹ is -NHC(O)NHR⁵ can be prepared.

Compounds of Formula I in which R¹ is -NHSO₂R⁵, in which R⁵ is as defined above with respect to Formula I, can be prepared by reacting a compound of Formula I in which R¹ is amino with an appropriate sulfonyl halide (e.g., 4-trifluorobenzenesulfonyl chloride, 1-pyrrolidine-sulfonyl chloride, 3-(5-trifluoromethyl-1-methylpyrazol-3-yl)-2-thiophene-sulfonyl chloride, etc.). The reaction is carried out in the presence of a suitable base (e.g., triethylamine, diisopropylethylamine, etc.) and in a suitable solvent (e.g., THF, 1-methyl-2-pyrrolidinone, DMF, dichloroethane, any appropriate mixture of suitable solvents, etc., preferably THF) at 0 to 60°C, preferably at approximately 25°C, requiring 0.5 to 24 hours (for further details see Example 27, infra.).

Compounds of Formula I in which R^3 is (C_{1-6}) alkyl (optionally substituted with a group selected from $-C(O)OH$, $-C(O)O(C_{1-4})$ alkyl, $-NHSO_2R^5$ and $-NHC(O)R^5$, in which R^5 is as defined above with respect to Formula I), hydroxyalkyl, phenyl (C_{1-4}) alkyl (optionally substituted with one or two radicals independently selected from amino, cyano, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, acetamido, methanesulfonamido, (C_{1-4}) alkyl, or (C_{1-4}) alkyloxy), or a group of Formula (a) can be prepared by reacting a compound of Formula I in which R^3 is hydro with a suitable alkylating agent (e.g., a compound of Formula 3). The reaction is carried out in a suitable solvent (e.g., DMF, any appropriate mixture of suitable solvents, etc.) typically at -10 to $40^\circ C$ and preferably at approximately $15^\circ C$, requiring 0.5 to 8 hours.

The *N*-oxides of the compounds of Formula I can be prepared by treating an unoxidized form of the compound of Formula I with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, etc.) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as methylene chloride) at approximately $0^\circ C$. Alternatively, the *N*-oxides of the compounds of Formula I can be prepared from the *N*-oxide of an appropriate starting material.

Compounds of Formula I in unoxidized form can be prepared from *N*-oxides of compounds of Formula I by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, etc.) in a suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, etc.) at 0 to $80^\circ C$.


Compounds of Formula I may be prepared as pharmaceutically acceptable acid addition salts by reacting the free base

forms of a compound of Formula I with a pharmaceutically acceptable inorganic or organic acid. Alternatively, the pharmaceutically acceptable base addition salts of compounds of Formula I may be prepared by reacting the free acid forms of compounds of Formula I with pharmaceutically acceptable inorganic or organic bases. Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds of Formula I are set forth in the definitions section of this application. Alternatively, the salt forms of the compounds of Formula I may be prepared using salts of the starting materials or intermediates.


The free acid or free base forms of the compounds of Formula I can be prepared from the corresponding base addition salt or acid addition salt form. For example, compounds of Formula I in an acid addition salt form may be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, etc.). Compounds of Formula I in a base addition salt form may be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc.).

In summary, an aspect of this invention is a process for preparing a compound of Formula I, in which each n , t and R^1 are as defined above with respect to Formula I; and the pharmaceutically acceptable salts and N -oxides thereof, which process comprises:

(a) alkylating a compound of Formula 2:




with a compound of Formula 3:



3

in which L is a leaving group and R⁶ and R⁷ form oxo or a
 5 carbonyl protective group, and deprotecting when necessary to
 give a compound of Formula I in which each n, t, u, X, Y, Z
 and R¹, R² and R³ are as defined above with respect to Formula
 I; or


10 (b) acylating a compound of Formula 4:



4

with a compound of Formula 5:


15



5

in which L is a leaving group, to give a compound of Formula I
 in which each n, t, u, X, Y, Z, R¹, R² and R³ are as defined
 20 above with respect to Formula I; or

(c) (1) alkylating 4-piperidone with a compound of Formula 3
 to give a compound of Formula 7:




in which R⁶ and R⁷ form oxo or a carbonyl protective group,

- 5 (2) reacting the compound of Formula 7 with a cyanide salt and ammonium carbonate and deprotecting when necessary to give a compound of Formula I in which X is NH, Y is C(O) and Z is C(O) and each n, t, u, R¹, R², R³ and R⁴ are as defined above with respect to Formula I; or

10

- (d) (1) reacting a compound of Formula 7 with a cyanide salt and sodium bisulfate to give a compound of Formula 9:




15

in which R⁶ and R⁷ form oxo or a carbonyl protective group, and

- 20 (2) reacting the compound of Formula 9 with chlorosulfonyl isocyanate and deprotecting when necessary to give a compound of Formula I in which X is O, Y is C(O), Z is C(O), R³ is hydro and each n, t, u, R¹ and R² are as defined above; or


- 25 (e) (1) reacting a compound of Formula 7 with trimethylsulfoxonium iodide to give a compound of Formula 12:



12

in which R⁶ and R⁷ form oxo or a carbonyl protective group,

- 5 (2) aminating the compound of Formula 12 with an amine of the formula NH₂R³ to give a compound of Formula 17:




17

10 and

- (3) reacting the compound of Formula 17 with 1,1'-carbonyldiimidazole or 1,1'-thiocarbonyldiimidazole and deprotecting when necessary to give a compound of Formula I in
15 which X is O, Y is CH₂ and Z is C(O) or C(S), respectively; or

- (f) (1) reacting a compound of Formula 7 with a cyanide salt and an ammonium salt to give a compound of Formula 14:



14


20

in which R⁶ and R⁷ form oxo or a carbonyl protective group and

(2) reacting the compound of Formula 14 with carbon oxysulfide or carbon disulfide and deprotecting when necessary to give a compound of Formula I in which X is NH, Y is C(S) and Z is C(O) or C(S), respectively; or

5

(g) (1) hydrolyzing a compound of Formula 14 to give a compound of Formula 18:



18

10

and

(2) reacting the compound of Formula 18 with 1,1'-carbonyldiimidazole or 1,1'-thiocarbonyldiimidazole to give a compound of Formula I in which X is NH, Y is C(O) and Z is C(O) or C(S), respectively;

(h) optionally further reducing a compound of Formula I in which R¹ is nitro to give a compound of Formula I in which R¹ is amino;

(i) optionally further reacting a compound of Formula I in which R¹ is amino with an isothiocyanate of the formula R⁵NC(S), in which R⁵ is as defined above with respect to Formula I, to give a corresponding compound of Formula I in which R¹ is -NHC(S)NHR⁵;

(j) optionally further reacting a compound of Formula I in which R¹ is amino with an isocyanate of the formula R⁵NC(O), in which R⁵ is as defined above with respect to Formula I, to give a corresponding compound of Formula I in which R¹ is -NHC(O)NHR⁵;

30

- (k) optionally further reacting a compound of Formula I in which R^1 is amino with an appropriate sulfonyl halide to give a compound of Formula I in which R^1 is $-NHSO_2R^5$, wherein R^5 is
5 as defined above with respect to Formula I;
- (l) optionally further alkylating a compound of Formula I in which R^3 is hydro with a suitable alkylating agent to give a compound of Formula I in which R^3 is hydro, (C_{1-6}) alkyl
10 (optionally substituted with a group selected from $-C(O)OH$, $-C(O)O(C_{1-4})$ alkyl, $-NHSO_2R^5$ and $-NHC(O)R^5$, in which R^5 is as defined above), hydroxyalkyl, phenyl (C_{1-4}) alkyl (optionally substituted with one or two radicals independently selected from amino, cyano, halo, hydroxy, nitro, trifluoromethyl,
15 trifluoromethoxy, acetamido, methanesulfonamido, (C_{1-4}) alkyl, or (C_{1-4}) alkyloxy), or a group of Formula (a);
- (m) de-alkylating a compound of Formula I in which R^3 is (C_{1-6}) alkyl to give a compound of Formula I in which R^3 is hydro;
20
- (n) optionally further oxidizing a compound of Formula I to give an *N*-oxide derivative thereof;
- (o) optionally further reducing an *N*-oxide derivative of a
25 compound of Formula I to unoxidized form;
- (p) optionally further converting a compound of Formula I into a pharmaceutically acceptable salt; and
- 30 (q) optionally further converting a salt form of a compound of Formula I to non-salt form.

In any of the above processes, a reference to Formula I refers to such Formula wherein each n , t , u , X , Y , Z , R^1 , R^2
35 and R^3 are as defined in their broadest definitions, with the

processes applying particularly well to the presently preferred embodiments.

Compounds of Formula 2 in which X is NH, Y is C(O), Z is C(O) and R³ is hydro (i.e., 1,3,8-triazaspiro[4.5]decane-2,4-diones) can be prepared by reacting a protected 4-piperidone (e.g., tert-butyl 4-oxopiperidine-1-carboxylate, 1-benzyl-4-piperidone, etc.) with cyanide salt and ammonium carbonate and then deprotecting. The reaction for preparing the protected 1,3,8-triazaspiro[4.5]decane-2,4-dione is carried out by proceeding as described above with respect to Scheme 3, but substituting the 4-piperidone for the compound of Formula 7. A convenient method of deprotecting when the protective group is tert-butoxycarbonyl is carried out with acid (e.g., hydrochloric acid, trifluoroacetic acid, etc.) with or without a suitable co-solvent (e.g., methanol, ethanol, 2-ethoxyethanol, any appropriate mixture of suitable alcohols, etc., preferably ethanol) at 0 to 100°C, typically at 20 to 80°C and preferably at reflux, requiring 0.1 to 2 hours. Further details of the reaction steps set forth in this paragraph are provided in Example 16, infra..

Compounds of Formula 2 in which X is O, Y is C(O), Z is C(O) and R³ is hydro (i.e., 3,8-diaza-1-oxaspiro[4.5]decane-2,4-diones) can be prepared by reacting a protected 4-piperidone with a cyanide salt and sodium bisulfate to give the corresponding 4-hydroxypiperidine-4-carbonitrile, reacting the nitrile with chlorosulfonyl isocyanate and then deprotecting. The process steps for preparing the protected 3,8-diaza-1-oxaspiro[4.5]decane-2,4-diones are carried out by proceeding as described above with respect to Scheme 4, but substituting the 4-piperidone for the compound of Formula 7 (for further details see Example 17, infra.).

Compounds of Formula 2 in which X is O, Y is CH₂ and Z is C(O) or C(S) (i.e., 3,8-diaza-1-oxaspiro[4.5]decane-2-ones and

-2-thiones) can be prepared by reacting a protected 4-piperidone with trimethylsulfoxonium iodide to give the corresponding 6-aza-1-oxa-spiro[2.3]octane, aminating the spirooctane with an amine of the formula NH_2R^3 to give the corresponding 4-aminomethyl-4-hydroxypiperidine, reacting the piperidine with 1,1'-carbonyldiimidazole or 1,1'-thiocarbonyldiimidazole, respectively, and deprotecting. The process steps for preparing the protected 3,8-diaza-1-oxaspiro[4.5]decane-2-ones and -2-thiones are carried out by proceeding as described above with respect to Scheme 5, but substituting the 4-piperidone for the compound of Formula 7 (for further details see Example 18, *infra*)).


Compounds of Formula 2 in which X is NH, Y is C(S) and Z is C(O) or C(S) and R^3 is hydro (i.e., 4-thioxo-1,3,8-triazaspiro[4.5]decane-2-ones and 1,3,8-triazaspiro[4.5]decane-2,4-dithiones) can be prepared by reacting a protected 4-piperidone with a cyanide salt and an ammonium salt to give the corresponding 4-aminopiperidine-4-carbonitrile, reacting the nitrile with carbon oxysulfide or carbon disulfide, respectively, and deprotecting. The process steps for preparing the protected 3,8-diaza-1-oxaspiro[4.5]decane-2-ones and 1,3,8-triazaspiro[4.5]decane-2,4-dithiones are carried out by proceeding as described above with respect to Scheme 6, but substituting the 4-piperidone for the compound of Formula 7.

Compounds of Formula 2 in which X is NH, Y is C(O) and Z is C(O) or C(S) and R^3 is hydro (i.e., 1,3,8-triazaspiro[4.5]decane-2,4-diones and 2-thioxo-1,3,8-triazaspiro[4.5]decane-4-ones) can be prepared by hydrolyzing a corresponding 4-aminopiperidine-4-carbonitrile, prepared as described above in the preceding paragraph, to give the corresponding 4-aminopiperidine-4-carboxamide, reacting the carboxamide with 1,1'-carbonyldiimidazole or 1,1'-thiocarbonyldiimidazole, respectively, and then deprotecting. The process steps for

preparing the protected 1,3,8-triazaspiro[4.5]decanones are carried out by proceeding as described above with respect to Scheme 7, but substituting the 4-aminopiperidine-4-carbonitrile for the compound of Formula 14. A convenient method of deprotecting when the protective group is benzyl is carried out by hydrogenating in the presence of a suitable catalyst (e.g., 10% Pd/C, palladium hydroxide, palladium, palladium oxide, nickel, palladium acetate, etc., preferably 10% Pd/C) optionally in the presence of acid and in a suitable solvent, typically an alcohol (e.g., methanol, ethanol, 2-ethoxyethanol, any appropriate mixture of suitable alcohols, etc.) or an alcohol/water mixture and preferably ethanol, typically at 0 to 100°C and preferably at approximately 25°C and typically at 15 to 60 psi and preferably at approximately 50 psi.

Compounds of Formula 2 in which R³ is hydro, optionally substituted (C₁₋₆)alkyl, hydroxyalkyl, or optionally substituted phenyl(C₁₋₄)alkyl can be prepared by alkylating a compound of Formula 2 in which R³ is hydro. The reaction is carried out with an appropriate alkylating agent (e.g., dimethylsulfate, N-(3-chloropropyl)-4-methoxybenzene-sulfonamide, etc.) in a suitable solvent (e.g., DMF, water, 1-methyl-2-pyrrolidinone, any appropriate mixture of suitable solvents, etc., preferably DMF) at -20 to 40°C, typically at 0 to 40°C and preferably at approximately 25°C (for further details see Example 19, *infra*).

Compounds of Formula 3 can be prepared by reacting an appropriately substituted benzoic acid chloride with N,O-dimethylhydroxylamine hydrochloride to give a compound of Formula 19:



19

in which each t , u , R^1 and R^2 are as defined above with respect to Formula I (provided that R^1 cannot be amino, nitro, thiocarbamoyl, thioureido, ureido, $-\text{NHSO}_2\text{R}^5$, $-\text{NHC}(\text{O})\text{R}^5$, $-\text{NHC}(\text{O})\text{NHR}^5$, $-\text{NHC}(\text{S})\text{NHR}^5$ and $-\text{SO}_2\text{NHR}^5$) and reacting the compound of Formula 19 with a 1-metalated ω -halo($\text{C}_2\text{-}_6$)alkane, typically a lithium ω -halo-1-($\text{C}_2\text{-}_6$)alkanide and preferably a lithium ω -chloro-1-($\text{C}_2\text{-}_5$)alkanide. Suitable benzoic acid chlorides are prepared by reacting a correspondingly substituted benzoic acid with an appropriate halogenating agent (e.g., thionyl chloride, oxalyl chloride, phosphorus pentachloride, etc.) and in a suitable solvent (e.g., methylene chloride, dichloroethane, any appropriate mixture of suitable solvents, etc., preferably methylene chloride) at 10 to 40°C, typically at 15 to 30°C and preferably at approximately 25°C, and requires 2 to 18 hours. Suitably substituted benzoic acids are commercially available or can be prepared by methods known in the art (for further details see Examples 1, 2 and 3, *infra*).

The reaction with the *N,O*-dimethylhydroxylamine hydrochloride is carried out in a suitable solvent (e.g., methylene chloride, THF, ethyl acetate, any appropriate mixture of suitable solvents, etc., preferably a mixture of THF and methylene chloride) at -10 to 80°C, typically at 0 to 50°C and preferably at 25°C, and requires 0.2 to 6 hours. The 1-metalated ω -haloalkane is prepared by cooling a solution of an appropriate dihaloalkane, typically a ω -chloro-1-iodo-($\text{C}_2\text{-}_5$)alkane, in a suitable inert organic solvent, preferably an ether (e.g., THF, diethyl ether, any appropriate mixture of

suitable solvents, etc., preferably a mixture of diethyl ether and pentane), typically to between -90 and -35°C and preferably to approximately -65°C, adding an organometallic base, typically an alkylmetallic base and preferably an alkyl
5 alkali metal base (e.g., *t*-butyllithium, *n*-butyllithium, *s*-butyllithium, *n*-butylsodium, *n*-butylpotassium, lithium diisopropylamide (LDA), etc., preferably *t*-butyllithium), at a rate such that the reaction temperature remains below -45°C, preferably below -55°C, and then allowing the reaction to
10 proceed at approximately -60°C, for 10 minutes to 5 hours. The compound of Formula 17 is then added as a solution to the cooled mixture containing the 1-metalated ω -haloalkane at a rate such that the reaction temperature remains below -40°C and then the reaction mixture is allowed to gradually warm to
15 between -20 to 20°C, preferably to approximately 15°C, over 1 to 6 hours. Further details of the reaction steps set forth in this and the preceding paragraph are provided in Example 7, *infra*..

20 Compounds of Formula 3 in which R¹ is halo can be prepared by first halogenating the corresponding compound of Formula 17 in which R¹ is hydro. The halogenation is carried out with a suitable halogenating agent (e.g., *N*-chloro-succinimide, chlorine, 1,3-dichloro-5,5-dimethylhydantoin,
25 etc.) in a suitable solvent (e.g., acetonitrile, acetic acid, DMF, any appropriate mixture of suitable solvents, etc., preferably acetonitrile) preferably at approximately 50°C (for further details see Example 5, *infra*.).

30 Alternatively, compounds of Formula 3 can be prepared by acylating an appropriately substituted benzene derivative of Formula 4 with an appropriate activated 1-(C₃₋₇)alkanone (i.e., of the formula LC(O)(CH₂)_nL in which L is a leaving group, preferably wherein *n* is 6). The acylation is carried
35 out by proceeding as described above with respect to Scheme 2, but substituting the activated 1-(C₃₋₇)alkanone for the

compound of Formula 5 (for further details see Example 8, *infra.*).

Compounds of Formula 3 in which t is 2, u is 0 and two adjacent R^1 radicals form a α,β -ethylenedioxy can be conveniently prepared by acylating 6,7-dichloro-1,4-benzodioxan with an appropriate activated 1-(C_{3-7})alkanone and then removing the chloro groups. Removal of the chloro groups can be effected by stirring under a hydrogen atmosphere with a suitable base (e.g., sodium hydroxide, lithium hydroxide, sodium acetate, etc.) and an appropriate catalyst (e.g., 10% Pd/C, nickel, etc, preferably 10% Pd/C) in a suitable solvent, typically an alcohol (e.g., methanol, ethanol, 2-ethoxyethanol, any appropriate mixture of suitable alcohols, etc.) and preferably methanol, at 0 to 60°C, typically at 15 to 40°C and preferably at approximately 25°C, requiring 2 to 48 hours (for further details see Example 9, *infra.*).

Compounds of Formula 3 in which R^6 and R^7 form a carbonyl protective group can be prepared by reacting a compound of Formula 3 in which R^6 and R^7 form oxo with a suitable protecting agent (e.g., ethylene glycol). For example, a compound of Formula 3 in which R^6 and R^7 form ethylenedioxy can be prepared by reacting the unprotected compound of Formula 3 with ethylene glycol in a suitable inert organic solvent (e.g., toluene, benzene, any appropriate mixture of suitable solvents, etc., preferably toluene) and preferably at reflux (for further details see Example 10, *infra.*).

Compounds of Formula 3 in which R^2 is (C_{1-4})alkyloxy or aryl(C_{1-4})alkyloxy can be prepared by reacting a compound of Formula 3 in which R^2 is hydroxy with a suitable alkylating agent (e.g., iodomethane, dimethylsulfate, iodoethane, benzylchloride, 2-iodopropane, etc.). Typically, R^6 and R^7 comprise a carbonyl protective group, preferably

ethylenedioxy, when n is 2 or 3. The alkylation is carried out in the presence of a suitable base (e.g., sodium hydride, potassium carbonate, diisopropylethylamine, etc., preferably sodium hydride) in a suitable inert organic solvent (e.g.,
5 DMF, 2-butanone, 1-methyl-2-pyrrolidinone, any appropriate mixture of suitable solvents, etc., preferably DMF) at -10 to 60°C, typically at 0 to 40°C and preferably at approximately 25°C, and requires 0.5 to 8 hours (for further details see Example 11, *infra.*). The protective group is
10 optionally removed by proceeding as described above with respect to Scheme 1.

Compounds of Formula 3 in which R^1 is nitro can be prepared by nitrating a compound of Formula 3 in which R^1 is
15 hydro with a suitable nitrating agent (e.g., acetyl nitrate, nitric acid, sodium nitrate, etc.) in a suitable solvent (e.g., acetic anhydride, acetic acid, any appropriate mixture of suitable solvents, etc., preferably acetic anhydride). For example, the nitration can be conveniently carried out with
20 acetyl nitrate, typically formed *in situ* by reaction of copper(II) nitrate with acetic anhydride, at 0 to 30°C, typically at 5 to 20°C and preferably at approximately 15°C, and requires 2 to 8 hours (for further details see Example 12, *infra.*).

25

Compounds of Formula 3 in which R^1 is amino can be prepared by reducing a compound of Formula 3 in which R^1 is nitro. The reduction can be carried out with a suitable chemical reducing agent or by catalytic hydrogenation. For
30 example, the reduction is conveniently carried out by hydrogenating under conditions similar to those described above for reducing compounds of Formula I in which R^1 is nitro (for further details see Example 13, *infra.*).

35 Compounds of Formula 3 in which R^1 is $-NHC(O)R^5$ in which R^5 is as defined above with respect to Formula I can be

prepared by reacting a compound of Formula 3 in which R^1 is amino with an appropriate acylating agent (e.g., acyl halides such as acetyl chloride, benzoyl chloride, nicotinoyl chloride, etc.). The reaction is carried out in a suitable solvent (e.g., methylene chloride, THF, pyridine, water, any appropriate mixture of suitable solvents, etc., preferably pyridine) at -10 to 40°C, typically at 15 to 35°C and preferably at approximately 25°C, and requires 0.5 to 8 hours.

10 Compounds of Formula 3 in which R^1 is $-NHSO_2R^5$ in which R^5 is as defined above with respect to Formula I can be prepared by reacting a compound of Formula 3 in which R^1 is amino with an appropriate sulfonyl halide (e.g., 4-trifluorobenzenesulfonyl chloride, 1-pyrrolidinesulfonyl chloride, 2-thiophenesulfonyl chloride, etc.). The reaction is carried out in by proceeding as described above for preparing compounds of Formula I in which R^1 is $-NHSO_2R^5$ from corresponding compounds in which R^1 is amino (for further details see Example 14, infra.).

20 Compounds of Formula 3 in which R^1 is $-NHC(S)NHR^5$ or $-NHC(O)NHR^5$ can be prepared by reacting a compound of Formula 3 in which R^1 is amino with an isothiocyanate of the formula $R^5NC(S)$ or an isocyanate of the formula $R^5NC(O)$, in which R^5 is as defined above with respect to Formula I. The reaction is carried out by proceeding as described above for preparing compounds of Formula I in which R^1 is $-NHC(S)NHR^5$ from corresponding compounds in which R^1 is amino (for further details see Example 15, infra.).

30 Compounds of Formula 4 are commercially available or can be made by processes known to those of ordinary skill in the art. For example, a compound of Formula 4 in which t is 3, u is 1, two adjacent R^1 radicals form ethylenedioxy, a third R^1 radical is chloro and R^2 is chloro (i.e., 6,7-dichloro-1,4-benzodioxan) can be prepared by halogenating 1,4-benzo-

dioxan. The halogenation is carried out with a suitable halogenating agent (e.g., *N*-chlorosuccinimide, chlorine, 1,3-dichloro-5,5-dimethylhydantoin, etc.) in a suitable solvent (e.g., acetic acid, DMF, acetonitrile, any appropriate mixture of suitable solvents, etc., preferably acetic acid) at approximately 120°C (for further details see Example 6, *infra.*).

Compounds of Formula 4 in which R¹ is -NHSO₂R⁵, in which R⁵ is as defined above with respect to Formula I, can be prepared by reacting a compound of Formula 4 in which R¹ is amino with an appropriate sulfonyl halide (e.g., 4-trifluorobenzenesulfonyl chloride, 1-pyrrolidine-sulfonyl chloride, 3-(5-trifluoromethyl-1-methylpyrazol-3-yl)-2-thiophene-sulfonyl chloride, etc.). The reaction is carried out in the presence of a suitable base (e.g., triethylamine, diisopropylethylamine, etc.) and in a suitable solvent (e.g., THF, 1-methyl-2-pyrrolidinone, DMF, dichloroethane, any appropriate mixture of suitable solvents, etc., preferably THF) at approximately reflux, requiring approximately 48 hours.

Compounds of Formula 5 can be prepared by reacting a protected acid of the formula L(CH₂)_nCOOH (e.g., *tert*-butyl ω-halo(C₂₋₆)alkanoate) deprotecting and then activating (e.g., convert to the corresponding acid halide).

EXAMPLE 1

Methyl 6-methoxy-1,3-benzodioxole-5-carboxylate

A mixture of methyl 1,3-benzodioxole-5-carboxylate (9.3 g, 51 mmol) acetic acid (25 ml) and fuming nitric acid (50 ml) was stirred approximately 15 minutes and then poured into ice-water (600 ml). The mixture was allowed to stand 1 hour in an ice-bath and the solids were collected, stirred

with water and recollected to give methyl 6-nitro-1,3-benzodioxole-5-carboxylate.

A mixture of the methyl 6-nitro-1,3-benzodioxole-5-carboxylate, 5% palladium on carbon (1.5 g), ethyl acetate (180 ml) and methanol (80 ml) was stirred 3 hours under a hydrogen atmosphere (15 psi). The mixture was filtered and concentrated and the residue was recrystallized from cyclohexane (200 ml) to give methyl 6-amino-1,3-benzodioxole-5-carboxylate (6.3 g, 32 mmol), m.p. 107-108°C.

A mixture of methyl 6-amino-1,3-benzodioxole-5-carboxylate (6.3 g, 32 mmol), concentrated sulfuric acid (7 ml) and water (35 ml) was cooled in an ice-bath and then a mixture of sodium nitrite (2.3 g, 33 mmol) and water (15 ml) was added. The mixture was diluted with 50 ml of water and added to a boiling solution of cupric sulfate pentahydrate (35 g, 140 mmol) and water (75 ml). The mixture was heated 10 minutes at boiling and then cooled in an ice-bath and extracted with diethyl ether (3x). The combined extracts were washed with water (4x) and brine (1x), dried (K_2CO_3) and concentrated. The residue was purified by column chromatography eluting with hexane/ethyl acetate (98:2-97:3) to give methyl 6-hydroxy-1,3-benzodioxole-5-carboxylate (2.7 g, 14 mmol), m.p. 100-101°C.

A mixture of methyl 6-hydroxy-1,3-benzodioxole-5-carboxylate (2.7 g, 14 mmol), sodium hydride (456 mg, 19 mmol, 760 mg of a 60% dispersion in mineral oil), iodomethane (1.9 g, 13 mmol) and DMF (approximately 35 ml) was stirred 2 hours. The mixture was poured into ice-water and the mixture was extracted with diethyl ether (2x). The combined extracts were washed with water (3x) and brine (1x) and concentrated to give methyl 6-methoxy-1,3-benzodioxole-5-carboxylate (3 g, 14 mmol), m.p. 74-75°C.

EXAMPLE 2

Ethyl 2-methoxy-5-phenoxybenzoate

5 A mixture of methyl 5-iodo-2-methoxybenzoate (14 g, 48 mmol), 30% aqueous sodium hydroxide (40 ml) and methanol (200-300 ml) was allowed to stand approximately 2 hours and then heated 5 minutes at reflux. The mixture was concentrated and the residue was stirred with water (500 ml). The mixture
10 was treated with 10% hydrochloric acid (200 ml) and then cooled to 10°C and the solids were collected and dried under vacuum at 90°C to give 5-iodo-2-methoxy-benzoic acid (13.4 g, 48 mmol), m.p. 150-152°C.

15 A mixture of 5-iodo-2-methoxybenzoic acid (13.4 g, 48 mmol), acetyl chloride (1 ml) and ethanol (50 ml) was heated 4 hours with stirring at reflux. The mixture was concentrated and the residue was dissolved in diethyl ether. The solution was poured into ice-cold saturated sodium
20 bicarbonate and the organic phase was washed with brine, dried (K₂CO₃), filtered and concentrated to give ethyl 5-iodo-2-methoxybenzoate (13.5 g, 44 mmol) as an oil.

 A mixture of ethyl 5-iodo-2-methoxybenzoate (4.1 g, 13.4
25 mmol), sodium phenoxide (1.7-1.8 g, 15 mmol), copper(I) oxide (1.1 g, 7.5 mmol) and dimethylacetamide (approximately 15 ml) was heated 4 hours with stirring at 180°C. The mixture was filtered, diluted with water and extracted with pentane/diethyl ether (7:3, 2x 100 ml). The combined extracts
30 were washed with dilute sodium hydroxide (3x) and water (1x), dried (K₂CO₃), filtered and concentrated. The residue was dried (P₂O₅) under vacuum to give crude product (1.17 g) which was combined with crude product (2.4 g) similarly prepared from methyl 5-iodo-2-methoxybenzoate (6 g, 19.6 mmol). The
35 combined crude product was purified by column chromatography

eluting with hexane/acetone (96:4) to give ethyl 2-methoxy-5-phenoxybenzoate (2 g, 7.3 mmol), m.p. 52-52°C.

EXAMPLE 3

5

6-Methoxy-1,3-benzodioxole-5-carboxylic acid

A mixture of methyl 6-methoxy-1,3-benzodioxole-5-carboxylate (3 g, 14 mmol), prepared as in Example 1, 20% sodium hydroxide (50 ml) and ethanol (25 ml) was heated 1 hour at reflux and then diluted with water, washed with diethyl ether (2x), treated with concentrated hydrochloric acid and cooled in an ice-bath. The solids were collected, washed with water (2x) and dried under vacuum at 70°C to give 6-methoxy-1,3-benzodioxole-5-carboxylic acid (2.3 g, 12 mmol), m.p. 151°C.

Proceeding similarly as in Example 3 with different starting materials gave 2-methoxy-5-phenoxybenzoic acid.

20

EXAMPLE 4

N-Methoxy-*N*-methyl-5-chloro-2-methoxybenzamide

The following is the preparation of a compound of Formula 17 in which *t* is 1, *u* is 1, R¹ is chloro at the β-position and R² is methoxy.

A mixture of 5-chloro-*o*-anisic acid (50 g, 0.27 mol), oxalyl chloride (23 ml, 0.27 mol) and methylene chloride was stirred 1 hour at approximately 25°C and then treated with DMF (2 drops). The mixture was stirred an additional hour, heated 45 minutes at reflux and then concentrated. The residue was dissolved in THF and the solution was reconcentrated. The residue was dissolved in THF (approximately 200 ml) and the solution was added in a thin stream to a mixture of

triethylamine (96 ml, 0.7 mol), *N,O*-dimethylhydroxylamine hydrochloride (26.3 g, 0.27 mol) and methylene chloride (approximately 300 ml). After an exothermic reaction had ensued, the mixture was allowed to cool to 25°C and stirred
5 approximately 16 hours. The mixture was filtered, concentrated and then partitioned between ethyl acetate and water. The organic layer was separated, washed with water (2x), sodium bicarbonate (2x), 2% hydrochloric acid (1x) and brine (1x), dried (K₂CO₃), filtered and concentrated to give
10 *N*-methoxy-*N*-methyl-5-chloro-2-methoxy-benzamide (52.3 g, 0.23 mmol), m.p. 80-83°C.

Proceeding similarly as in Example 4 with different starting materials gave the following compounds of Formula 17:

- 15 *N*-methoxy-*N*-methyl-2-methoxybenzamide,
N-methoxy-*N*-methyl-2,5-dichlorobenzamide,
N-methoxy-*N*-methyl-2,5-dimethoxybenzamide,
N-methoxy-*N*-methyl-2,4,5-trimethoxybenzamide,
20 *N*-methoxy-*N*-methyl-5-chloro-2-ethoxybenzamide,
N-methoxy-*N*-methyl-4-chloro-2-ethoxybenzamide,
N-methoxy-*N*-methyl-4-methoxybiphenyl-3-carboxamide,
N-methoxy-*N*-methyl-4-chloro-2-methoxybenzamide,
N-methoxy-*N*-methyl-2-methoxy-1-naphthalenecarboxamide,
25 *N*-methoxy-*N*-methyl-3-methoxynaphthalenecarboxamide,
N-methoxy-*N*-methyl-6-methoxy-2-naphthalenecarboxamide,
N-methoxy-*N*-methyl-2-methoxy-5-phenoxybenzamide,
N-methoxy-*N*-methyl-2-benzyloxy-5-chlorobenzamide,
N-methoxy-*N*-methyl-3,5-dichloro-2-methoxybenzamide,
30 *N*-methoxy-*N*-methyl-6-bromo-2-methoxy-1-naphthalenecarboxamide
and
N-methoxy-*N*-methyl-6-methoxy-1,3-benzodioxole-5-carboxamide.

EXAMPLE 5*N*-Methoxy-*N*-methyl-5-chloro-2,4-dimethoxybenzamide

5 The following is the preparation of a compound of Formula 17 in which *t* is 2, *u* is 1, *R*¹ is chloro and methoxy at the β- and γ-positions, respectively, and *R*² is methoxy.

 A mixture of *N*-methoxy-*N*-methyl-2,4-dimethoxybenzamide
10 (7.2 g, 32 mmol), prepared as in Example 4, *N*-chlorosuccinimide (4.8 ml, 36 mmol) and acetonitrile (100 ml) was heated 16 hours at 50°C. The mixture was concentrated and the residue was partitioned between ethyl acetate (300 ml) and saturated sodium bicarbonate (150 ml).
15 The mixture was filtered and the organic layer was separated, washed with water (4x) and brine (1x), dried (K₂CO₃), filtered through a short column of silica-gel and concentrated to give *N*-methoxy-*N*-methyl-5-chloro-2,4-dimethoxybenzamide (5.3 g, 20 mmol), m.p. 97-99°C.

20

EXAMPLE 6

6,7-Dichloro-1,4-benzodioxan

25 The following is the preparation of a compound of Formula 4 in which *t* is 3, *u* is 1, two adjacent *R*¹ radicals form ethylenedioxy, a third *R*¹ radical is chloro and *R*² is chloro.

 A mixture of 1,4-benzodioxan (59.5 g, 0.437 mol)
30 *N*-chlorosuccinimide (121.5 g, 0.91 mol) and acetic acid (150 ml) was heated 30 minutes with stirring at 120°C and then allowed to cool to approximately 25°C and diluted with water (400 ml). The solids were collected, washed with water, stirred with a mixture of ethyl acetate (900 ml) and toluene
35 (250 ml), recollected, stirred with water and dried at 60°C to give 6,7-dichloro-1,4-benzodioxan (16 g, 78 mmol),

m.p. 149-151°C. The ethyl acetate/toluene solution was concentrated to approximately 200 ml, diluted with methanol (200 ml) and cooled in an ice-bath. The solids were collected, washed with cold methanol (200 ml) and dried at 60-70° to give
5 additional 6,7-dichloro-1,4-benzodioxan (43.5 g, 212 mmol), m.p. 148-150°C.

EXAMPLE 7

10 5-Chloro-1-(5-chloro-2-methoxyphenyl)-1-pentanone

The following is the preparation of a compound of Formula 3 in which L is chloro, n is 4, t is 1, u is 1, R¹ is chloro at the β-position, R² is methoxy and R⁶ and R⁷ form oxo.

15

A mixture of 5-chloro-1-iodobutane (30 g, 137.6 mmol), ether (300 ml) and pentane (500 ml) was cooled to approximately -65°C and then *tert*-butyllithium (1.7 M, 160 ml, 0.27 moles) was added over 30 minutes such that the reaction
20 mixture remained below approximately -55°C. The mixture was cooled 1 hour with stirring at -65 to -60°C and then *N*-methoxy-*N*-methyl-5-chloro-2-methoxybenzamide (25 g, 0.11 mol), prepared as in Example 4, in THF (approximately 80 ml) was added. The mixture was diluted with additional ether
25 (300 ml), allowed to warm to 10°C and then combined with saturated ammonium chloride. The organic layer was separated, dried (K₂CO₃), filtered and concentrated. The residue was purified by column chromatography eluting with hexane/ethyl acetate (9:1 to 85:15) to give 5-chloro-1-(5-chloro-2-methoxy-
30 phenyl)-1-pentanone, m.p. 52-54°C.

Proceeding similarly as in Example 7 with different starting materials gave the following compounds of Formula 3:

- 35 5-chloro-1-(2-methoxyphenyl)-1-pentanone,
5-chloro-1-(2,5-dichlorophenyl)-1-pentanone,

5-chloro-1-(2,5-dimethoxyphenyl)-1-pentanone,
5-chloro-1-(4-methoxy-biphenyl-3-yl)-1-pentanone,
5-chloro-1-(2,4,5-trimethoxyphenyl)-1-pentanone,
5-chloro-1-(5-chloro-2-ethoxyphenyl)-1-pentanone,
5 5-chloro-1-(4-chloro-2-ethoxyphenyl)-1-pentanone,
5-chloro-1-(4-chloro-2-methoxyphenyl)-1-pentanone,
5-chloro-1-(2-methoxynaphthalen-1-yl)-1-pentanone,
5-chloro-1-(3-methoxynaphthalen-2-yl)-1-pentanone,
5-chloro-1-(6-methoxynaphthalen-2-yl)-1-pentanone,
10 5-chloro-1-(2-methoxy-5-phenoxyphenyl)-1-pentanone,
5-chloro-1-(2-benzyloxy-5-chlorophenyl)-1-pentanone,
5-chloro-1-(3,5-dichloro-2-methoxyphenyl)-1-pentanone,
5-chloro-1-(5-chloro-2,4,-dimethoxyphenyl)-1-pentanone,
5-chloro-1-(6-bromo-2-methoxynaphthalen-1-yl)-1-pentanone,
15 5-chloro-1-(2-methoxy-4,5-methylenedioxyphenyl)-1-pentanone
and
6-bromo-1-(5-chloro-2-methoxyphenyl)-1-hexanone.

EXAMPLE 7A

20

5-Chloro-1-(2,4,6-trimethoxyphenyl)-1-pentanone

The following is the preparation of a compound of Formula
3 in which L is chloro, n is 4, t is 2, u is 1, R¹ is methoxy
25 at the α - and γ -positions, R² is methoxy and R⁶ and R⁷ form
oxo.

A mixture of aluminum chloride (22.6 g, 170 mmol), 5-
chlorovaleryl chloride (26.4 g, 170 mmol), and 1,2-dichloro-
30 ethane (200 ml) was stirred for 30 minutes, and then filtered.
The filtrate was added to a solution of trimethoxybenzene
(26.7 g, 158 mmol) in 1,2-dichloroethane (100 ml); with
reaction mixture warming spontaneously to approximately 50°C.
Thin layer chromatography of a water-quenched sample taken
35 after four hours showed complete reaction. The reaction
mixture was poured over ice, and ethyl acetate was added to

extract the product. The ethyl acetate phase was washed twice with water and once with brine, then dried over anhydrous sodium sulfate. The solution was filtered and the solvent removed, then the resulting oil was dissolved in a warm 20% solution of ethyl acetate in hexane (250 ml). The solution was allowed to crystallize at room temperature for five hours, then at 4°C for one hour. Filtration, washing the crystals with 10% ethyl acetate in hexane, and air-drying afforded 5-chloro-1-(2,4,6-trimethoxyphenyl)-1-pentanone, 34 g (83% yield), m.p. 53-5°C.

EXAMPLE 8

7-Bromo-1-(5-chloro-2-methoxyphenyl)-1-heptanone

The following is the preparation of a compound of Formula 3 in which L is bromo, n is 6, t is 1, u is 1, R¹ is chloro at the β-position, R² is methoxy and R⁶ and R⁷ form oxo.

A mixture of 7-bromoheptanoic acid (7.6 g, 36.4 mmol), oxalyl chloride (4 ml, 45.8 mmol) and 1,2-dichloroethane (80 ml) was stirred 45 minutes at approximately 25°C and an additional 45 minutes at approximately 45°C and then concentrated. The residue was stirred approximately 16 hours with a mixture of aluminum chloride (4.3 g, 32 mmol), 4-chloroanisole (4 g, 28 mmol) and dichloroethane (approximately 200 ml). The mixture was then poured over cold dilute hydrochloric acid and diluted with methylene chloride. The organic layer was separated, washed with water (3x) and dried (K₂CO₃). The residue was purified by column chromatography eluting with hexane/ethyl acetate (95:5) to give 7-bromo-1-(5-chloro-2-hydroxyphenyl)-1-heptanone (250 mg, 0.78 mmol), m.p. 79-80°C and 7-bromo-1-(5-chloro-2-methoxyphenyl)-1-heptanone (3.3 g, 9.9 mmol) as an oil.

Proceeding similarly as in Example 8 with different starting materials gave the following compounds of Formula 3:

- 6-bromo-1-(2,4-dimethoxyphenyl)-1-hexanone as an oil;
5 6-bromo-1-(5-phenyl-2-methoxyphenyl)-1-hexanone as an oil;
5-chloro-1-(5-phenyl-2-methoxyphenyl)-1-pentanone as an oil;
6-bromo-1-(2-hydroxy-4-methoxyphenyl)-1-hexanone, m.p. 57-58°C;
5-chloro-1-(2,3-dichloro-5,6-ethylenedioxyphenyl)-1-pentanone,
10 m.p. 54-55°C; 4-chloro-1-(5-chloro-2-hydroxyphenyl)-1-butanone
and 4-chloro-1-(5-chloro-2-methoxyphenyl)-1-butanone as a
mixture;
6-bromo-1-(5-chloro-2-hydroxyphenyl)-1-hexanone and 6-bromo-
1-(5-chloro-2-methoxyphenyl)-1-hexanone as a mixture; and
15 N-[4-(5-chloropentanoyl)-2,5-dimethoxyphenyl]-
4-chlorobenzenesulfonamide, m.p. 116-119°C.

EXAMPLE 9

20 5-Chloro-1-(2,3-ethylenedioxyphenyl)-1-pentanone

The following is the preparation of a compound of Formula 3 in which L is chloro, n is 4, t is 2, u is 0, two adjacent R¹ radicals form a,β-ethylenedioxy and R⁶ and R⁷ form oxo.

25

- A mixture of 5-chloro-1-(5,6-ethylenedioxy-2,3-dichloro-phenyl)-1-pentanone (4.9 g, 15.2 mmol), prepared as in Example 8, 10% palladium on carbon (900 mg), 10% sodium hydroxide (40-50 ml) and methanol (200 ml) was stirred 24 hours under a
30 hydrogen atmosphere. The mixture was filtered and concentrated and the residue was dissolved in water. The solution was extracted with ether/hexane (8:2; 1x 100 ml) and the extract was concentrated. The residue was purified by column chromatography eluting with hexane/ethyl acetate (9:1)
35 to give 5-chloro-1-(2,3-ethylenedioxyphenyl)-1-pentanone (2.1 g, 8.3 mmol), m.p. 32-38°C.

EXAMPLE 10

5-Chloro-1-(5-chloro-2-methoxyphenyl)-1,1-ethylenedioxy-pentane

5

The following is the preparation of a compound of Formula 3 in which L is chloro, n is 4, t is 1, u is 1, R¹ is chloro at the β-position, R² is methoxy and R⁶ and R⁷ form ethylenedioxy.

10

A mixture of 5-chloro-1-(5-chloro-2-methoxyphenyl)-1-pentanone (2 g, 7.66 mmol), prepared as in Example 7, ethylene glycol (1.25 g, 20 mmol), 2-naphthalenesulfonic acid (50 mg, 0.24 mmol) and toluene (approximately 80 ml) was heated 4-5 hours at reflux (removing water with a Dean-Stark trap) and then additional ethylene glycol (1 g, 16 mmol) was added. The mixture was heated approximately 16 hours at reflux and then washed with saturated sodium bicarbonate, water (3x) and brine (1x), dried (K₂CO₃), filtered and concentrated to give 5-chloro-1-(5-chloro-2-methoxyphenyl)-1,1-ethylenedioxy-pentane (2.23 g, 7.31 mmol) as an oil.

Proceeding similarly with different starting materials gave the following compounds of Formula 3:

5-(5-chloro-1,1-ethylenedioxy-pentyl)-1,4-benzodioxan as an oil; and 4-chloro-1-(5-chloro-2-hydroxyphenyl)-1,1-ethylenedioxybutane as an oil.

EXAMPLE 11

30

4-Chloro-1-(5-chloro-2-methoxyphenyl)-1,1-ethylenedioxybutane

The following is the preparation of a compound of Formula 3 in which L is chloro, n is 3, t is 1, u is 1, R¹ is chloro at the β-position, R² is methoxy and R⁶ and R⁷ form ethylenedioxy.

A mixture of 4-chloro-1-(5-chloro-2-hydroxyphenyl)-1,1-ethylenedioxybutane (0.86 g, 2.5 mmol) sodium hydride (0.18 g, 4.5 mmol in mineral oil) and DMF (3 ml) was stirred 5 30 minutes. The mixture was cooled to approximately 0°C and dimethyl sulfate (0.44 g, 3.5 mmol) was added. The mixture was heated 4 hours with stirring at approximately 25°C and then poured into ice cold water. The mixture was extracted with ether/pentane (7:3) and the extract concentrated to give 10 4-chloro-1-(5-chloro-2-methoxyphenyl)-1,1-ethylenedioxybutane (0.85 g, 2.4 mmol).

Proceeding similarly as in Example 11 with different starting materials gave 5-chloro-1-(2-benzyloxy-15 5-chlorophenyl)-1-pentanone.

EXAMPLE 12

5-Chloro-1-(2,4-dimethoxy-5-nitrophenyl)-1-pentanone 20

The following is the preparation of a compound of Formula 3 in which L is chloro, n is 4, t is 2, u is 1, R¹ is nitro and methoxy at the β- and γ-positions, respectively, R² is methoxy and R⁶ and R⁷ form oxo. 25

A mixture of 5-chloro-1-(2,4-dimethoxyphenyl)-1-pentanone (11.07 g, 43.12 mmol), prepared as in Example 7, and acetic anhydride (75 ml) was cooled at 5-6°C and then copper(II) nitrate hemipentahydrate (6.25 g, 25.9 mmol) was added. The 30 mixture was cooled approximately 6 hours with stirring at 15-16°C, filtered, poured into water, stirred with potassium carbonate and then extracted with ethyl acetate. The extract was washed with dilute ammonium hydroxide and then brine, dried (Na₂SO₄), filtered and concentrated. The residue was 35 recrystallized from ethyl acetate to give 5-chloro-1-(2,4-

dimethoxy-5-nitro-phenyl)-1-pentanone (8.81 g, 29.2 mmol),
m.p. 93-95°C.

Proceeding similarly as in Example 12 with different
5 starting materials gave the following compounds of Formula 3:

substituting 5-(5-chloro-1,1-ethylenedioxyphenyl)-
1,4-benzodioxan gave 5-(5-chloro-1,1-ethylenedioxyphenyl)-
7-nitro-1,4-benzodioxan, m.p. 74-76°C; and
10 substituting 5-chloro-1-(2-methoxyphenyl)-1-pentanone gave
5-chloro-1-(2-methoxy-3-nitrophenyl)-1-pentanone as an oil and
5-chloro-1-(2-methoxy-5-nitrophenyl)-1-pentanone,
m.p. 57-58°C.

15

EXAMPLE 12A

5-Chloro-1-(3-nitro-2,4,6-trimethoxyphenyl)-1-pentanone

The following is the preparation of a compound of Formula
20 3 in which L is chloro, n is 4, t is 3, u is 1, R¹ is nitro at
the β-position and methoxy at the α- and γ-positions,
R² is methoxy and R⁶ and R⁷ form oxo.

A mixture of 5-chloro-1-(2,4,6-trimethoxyphenyl)-
25 1-pentanone (41.5 g, 160 mmol), prepared as in Example 7A,
acetic acid (150 ml) and acetic anhydride (70 ml) was cooled
at 8°C and then copper(II) nitrate hemipentahydrate (14 g,
60.2 mmol) was added. The mixture was cooled approximately 3
hours with stirring at 15-18°C; then additional copper(II)
30 nitrate hemipentahydrate (5.5 g, 23.6 mmol) was added. The
mixture was cooled a further approximately 4 hours with
stirring at 15-18°C; then filtered, and the filtrate stored at
5°C for 16 hours. The filtrate was then poured into an
ice/water mixture, and potassium carbonate added with stirring
35 until the mixture remained alkaline. The mixture was then
extracted with ethyl acetate. The extract was washed with

dilute ammonium hydroxide and then brine, dried (Na_2SO_4), filtered and concentrated. The residue was purified by column chromatography eluting with hexane/methylene chloride/methanol (60:40:1) to give 5-chloro-1-(3-nitro-2,4,6-trimethoxyphenyl)-1-pentanone (8.4 g, 25 mmol) as an oil.

EXAMPLE 13

5-Chloro-1-(5-amino-2,4-dimethoxyphenyl)-1-pentanone

10

The following is the preparation of a compound of Formula 3 in which L is chloro, n is 4, t is 2, u is 1, R^1 is amino and chloro at the β - and γ -positions, respectively, R^2 is methoxy and R^6 and R^7 form oxo.

15

A mixture of 5-chloro-1-(2,4-dimethoxy-5-nitrophenyl)-1-pentanone (2.9 g, 9.6 mmol), prepared as in Example 12, 10% palladium on carbon (650 mg) and THF (approximately 170 ml) was stirred 3 hours under a hydrogen atmosphere (15 psi). The mixture was filtered and concentrated and the residue was purified by column chromatography eluting with hexane/ethyl acetate (60:40) to give 5-chloro-1-(5-amino-2,4-dimethoxyphenyl)-1-pentanone (1.9 g, 7 mmol), m.p. 87-88°C.

25

Proceeding similarly as in Example 13 with different starting materials gave 7-amino-5-(5-chloro-1,1-ethylenedioxy-pentyl)-1,4-benzodioxan as an oil; and (using the material from Example 12A) gave 5-chloro-1-(3-amino-2,4,6-trimethoxyphenyl)-1-pentanone (8.4 g, 25 mmol) as an oil.

30

EXAMPLE 14

N-[5-(5-Chloropentanoyl)-2,4-dimethoxyphenyl]-
4-trifluoromethylbenzenesulfonamide

5

The following is the preparation of a compound of Formula 3 in which L is chloro, n is 4, t is 2, u is 1, R¹ is 4-trifluoromethylphenylsulfonylamino and methoxy at the β- and γ-positions, respectively, R² is methoxy and R⁶ and R⁷ form

10 oxo.

A mixture of 1-(5-amino-2,4-dimethoxyphenyl)-5-chloro-1-pentanone (0.54 g, 2 mmol), prepared as in Example 13, 4-trifluoromethylbenzenesulfonyl chloride (0.51 g, 2.1 mmol) 15 triethylamine (0.25 g, 2.5 mmol) and THF (approximately 50 ml) was stirred 16 hours at approximately 25°C. The mixture was concentrated and the residue was partitioned between ethyl acetate and dilute ammonium hydroxide. The organic layer was washed with water (1x) and then brine (1x), dried (K₂CO₃), 20 filtered and concentrated to give *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-4-trifluoromethylbenzenesulfonamide (0.8 g, 1.7 mmol), m.p. 150-153°C.

Proceeding similarly as in Example 14 with different 25 starting materials gave the following compounds of Formula 3.

N-[3-(5-chloropentanoyl)-4-methoxyphenyl]acetamide,
N-[2-chloro-4-(5-chloro-pentanoyl)-5-methoxyphenyl]acetamide,
N-{4-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]- 30 sulfamoyl]phenyl}acetamide, *N*-[3-(5-chloropentanoyl)-4-methoxyphenyl]benzamide,
N-[3-(5-chloropentanoyl)-4-methoxyphenyl]-2-chlorobenzamide,
N-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]pyridine-4-carboxamide, *N*-[3-(5-chloropentanoyl)-4-methoxyphenyl]- 35 benzenesulfonamide,

- N*-[3-(5-chloro-pentanoyl)-4-methoxyphenyl]-1-pyrrole-sulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-methanesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]benzenesulfonamide, *N*-[5-(5-chloropentanoyl)-
- 5 2,4-dimethoxyphenyl]-4-toluenesulfonamide, m.p. 152-153°C, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]biphenyl-sulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-1-pyridinesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-1-thiophenesulfonamide, *N*-[3-(5-chloropentanoyl)-
- 10 4-methoxyphenyl]-4-chlorobenzenesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-2-naphthalene-sulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-4-aminobenzenesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-4-cyanobenzenesulfonamide,
- 15 *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-4-nitrobenzene-sulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-2-chlorobenzenesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-3-chlorobenzenesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-4-chlorobenzene-
- 20 sulfonamide, *N*-[3-(5-chloropentanoyl)-4-methoxyphenyl]-3,4-dimethoxybenzenesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-4-methoxybenzenesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-4-(prop-2-yl)benzenesulfonamide, *N*-[3-(5-chloropentanoyl)-4-methoxy-
- 25 phenyl]-*N*-phenylsulfonylbenzenesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-2,4-difluorobenzenesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-3,4-difluorobenzenesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-5-chloro-
- 30 2-thiophenesulfonamide, *N*-[5-(5-chloropentanoyl)-2,4,6-trimethoxyphenyl]-4-trifluoromethylbenzene-sulfonamide, m.p. 128-130°C, *N*-[5-(5-chloropentanoyl)-
- 35 2,4-dimethoxyphenyl]-3-trifluoromethylbenzenesulfonamide,

- N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-5-pyrid-2-yl-2-thiophenesulfonamide,
N-[5-(5-chloropentanoyl)-2,4-dimethoxy-phenyl]-4-trifluoromethoxybenzenesulfonamide,
5 *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-4-trifluoromethoxybenzenesulfonamide,
N-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-3,5-di(trifluoromethyl)benzenesulfonamide,
10 *N*-[3-(5-chloropentanoyl)-4,5-ethylenedioxyphenyl]-4-trifluoromethylbenzenesulfonamide,
N-[5-(5-chloro-1,1-ethylenedioxy-pentyl)-3,4-ethylenedioxyphenyl]-4-trifluoromethylbenzenesulfonamide;
N-[5-(5-chloro-pentanoyl)-2,4-dimethoxyphenyl]-2-(5-trifluoromethylpyrid-2-ylsulfonyl)-4-thiophenesulfonamide and
15 *N*-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-5-(5-trifluoromethylpyrid-2-ylsulfonyl)-2-thiophenesulfonamide.

EXAMPLE 15

20

1-[5-(5-Chloropentanoyl)-2,4-dimethoxyphenyl]-
3-(4-trifluoromethylphenyl)urea

- The following is the preparation of a compound of Formula
25 3 in which L is chloro, n is 4, t is 2, u is 1, R¹ is 4-trifluorophenylureido and methoxy at the β- and γ-positions, respectively, R² is methoxy and R⁶ and R⁷ form oxo.

- A mixture of 5-chloro-1-(5-amino-2,4-dimethoxyphenyl)-
30 1-pentanone (0.27 g, 1 mmol), prepared as in Example 14, a,a,a-trifluoro-*p*-tolyl isocyanate (0.16 ml, 1.1 mmol), toluene (3 ml) and ethyl acetate (0.5 ml) was heated 10 minutes with stirring at approximately 50°C. The mixture was concentrated and the residue was recrystallized from
35 hexane/ethyl acetate. The solids were collected and dried at 70°C to give 1-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-

3-(4-trifluoromethylphenyl)urea (0.43 g, 0.94 mmol),
m.p. 154-156°C.

Proceeding similarly as in Example 15 with different
5 starting materials gave the following compounds of Formula 3:

1-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-3-prop-2-ylurea,
1-[5-(5-chloro-pentanoyl)-2,4-dimethoxyphenyl]-3-(3-trifluoro-
methylphenyl)urea and
10 1-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-3-(2-trifluoro-
methylphenyl)urea.

EXAMPLE 16

15 1,3,8-Triazaspiro[4.5]decane-2,4-dione

The following is the preparation of a compound of Formula
2 in which X is NH, Y is C(O), Z is C(O) and R³ is hydro.

20 A mixture of tert-butyl 4-oxopiperidine-1-carboxylate
(156 g, 0.783 mol), potassium cyanide (150 g, 2.3 mol),
ammonium carbonate (370 g, 3.8 mol) and water (600 ml) was
heated at approximately 50°C. The mixture was diluted with
ethanol (750 ml) over 45 minutes and then 400 ml of solvent
25 was removed by distilling 1 hour at 65-85°C. The mixture was
diluted with water (300 ml), heated to 85°C, diluted with
additional water (500 ml), heated 30 minutes with stirring at
75°C and then cooled to 10°C. The solids were collected,
stirred with cold water (2x), recollected and dried at 60°C to
30 give tert-butyl 1,3,8-triaza-2,4-dioxo-8-spiro[4.5]decane-
carboxylate (122 g, 0.45 mol).

A slurry of tert-butyl 1,3,8-triaza-2,4-dioxo-8-
spiro[4.5]decane-carboxylate (122 g, 0.45 mol) and ethanol
35 (400 ml) was heated at reflux and then dilute portionwise with
a solution of hydrogen chloride in ethanol (prepared from

acetyl chloride (160 ml) and ethanol (500 ml)). The mixture was heated 15 minutes at reflux and then cooled to approximately 25°C and the solids were collected, washed with ethanol (approximately 130 ml) and dried to give 1,3,8-triaza-
5 spiro[4.5]decane-2,4-dione hydrochloride, m.p. >280°C (dec).

EXAMPLE 17

3,8-Diaza-1-oxaspiro[4.5]decane-2,4-dione

10

The following is the preparation of a compound of Formula 2 in which X is O, Y is C(O), Z is C(O) and R³ is hydro.

A slurry of 1-benzyl-4-piperidone (53.3 g, 0.28 mol),
15 sodium bisulfate (38.5 g, 0.32 mol), potassium cyanide (24.5 g, 0.38 mol) and water (200 ml) was stirred 1 hour and then combined with diethyl ether. The mixture was stirred 1 hour and the ether layer was separated, washed with water (2x) and brine (2x), dried (K₂CO₃), filtered and concentrated.
20 The residue was crystallized from pentane/diethyl ether (3:1, approximately 400 ml) to give 1-benzyl-4-hydroxy-piperidine-4-carbonitrile (45 g) as a crude material.

A mixture of crude 1-benzyl-4-hydroxypiperidine-
25 4-carbonitrile (9.5 g), chlorosulfonyl isocyanate (6.4 g, 45 mmol) and toluene (200 ml) was stirred 1.5 hours at 25°C, 3.5 hours at reflux and then approximately 12 hours at 25°C. The mixture was concentrated and the residue was dissolved in ethanol (25 ml) and concentrated hydrochloric acid (5 ml).
30 The solution was heated 7 days at reflux and concentrated. The residue was mixed with water (approximately 90 ml) and the solids were collected and dried to give 8-benzyl-3,8-diaza-1-oxa-spiro[4.5]decane-2,4-dione (5.4 g, 21 mmol), m.p. 291-294°C.

35

A mixture of 8-benzyl-3,8-diaza-1-oxaspiro[4.5]decane-2,4-dione (1.1 g, 4.2 mmol), 10% palladium on carbon (330 mg), acetic acid 10 ml, concentrated hydrochloric acid (2 ml) and water (20 ml) was hydrogenated approximately 12 hours at 15 psi of pressure. The mixture was filtered and concentrated and the residue was crystallized from isopropanol to give 3,8-diaza-1-oxa-spiro[4.5]decane-2,4-dione (0.6 g, 2.9 mmol).

EXAMPLE 18

3-tert-Butyl-3,8-diaza-1-oxaspiro[4.5]decane-2-one

The following is the preparation of a compound of Formula 2 in which X is O, Y is CH₂, Z is C(O) and R³ is tert-butyl.

A mixture of trimethylsulfoxonium iodide (27 g, 123 mmol), sodium hydride (3 g, 125 mmol) and DMSO (60 ml) was stirred 15-20 minutes under argon and then 1-benzyl-4-piperidone (22.7 g, 120 mmol) in DMSO (60 ml) was added. The mixture was stirred 1 hour at 25°C and 1 hour at 50°C, poured into water (1 L) and extracted with diethyl ether/hexane (1:1). The extract was dried (Na₂SO₄) and concentrated to give 6-aza-6-benzyl-1-oxaspiro[2.3]octane (21.4 g, 105 mmol).

A mixture of 6-aza-6-benzyl-1-oxaspiro[2.3]octane (10 g, 49 mmol), tert-butylamine (20-30 ml, 190-285 mmol) and THF (approximately 5 ml) was heated 32 hours at 120°C. The mixture was concentrated and extracted with methylenechloride. The extract was dried (Na₂SO₄) and concentrated. The residue was stirred in heptane and then reisolated by filtration to give (tert-butyl)(1-benzyl-4-hydroxypiperidin-4-ylmethyl)amine (11.9 g, 43 mmol), m.p. 161-162°C.

A mixture of (tert-butyl)(1-benzyl-4-hydroxypiperidin-4-ylmethyl)amine (11.9 g, 43 mmol), 1,1'-carbonyldiimidazole (8.4 g, 52 mmol) and THF (150 ml) was heated 3.5 hours at

reflux. The mixture was cooled, poured into dilute hydrochloric acid and then washed with methylene chloride (2x 200 ml). The combined washes were extracted with dilute hydrochloric acid and the combined aqueous layers were treated with sodium hydroxide and extracted with methylene chloride. The extract was dried (Na_2SO_4) and concentrated and the residue was recrystallized from heptane to give 8-benzyl-3-tert-butyl-3,8-diaza-1-oxaspiro[4.5]decane-2-one (9.98 g, 33 mmol), m.p. 110-112°C.

10

A mixture of 8-benzyl-3-tert-butyl-3,8-diaza-1-oxaspiro[4.5]decane-2-one (9 g, 30 mmol), 10% palladium on carbon (0.9 g) and ethanol (100 ml) was stirred 6 to 7 hours under a hydrogen atmosphere (50 psi). The mixture was filtered and then concentrated to give crude 3-tert-butyl-3,8-diaza-1-oxa-spiro[4.5]decane-2-one (7.2 g), m.p. 108-111°C.

15

EXAMPLE 19

20

3-Methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione

The following is the preparation of a compound of Formula 2 in which X is NH, Y is C(O), Z is C(O) and R^3 is methyl.

25

A mixture of tert-butyl 2,4-dioxo-1,3,8-triaza-8-spiro[4.5]decane-carboxylate (4.9 g, 18.2 mmol), dimethylsulfate (2.9 g, 23 mmol), potassium carbonate (10.8 g, 78.3 mmol) and DMF (60 ml) was stirred approximately 60 hours at 25°C. The mixture was concentrated and the residue was partitioned between ethyl acetate and water. The ethyl acetate layer was separated, washed with water (3x), dried (Na_2SO_4), filtered and concentrated to give tert-butyl 2,4-dioxo-3-methyl-1,3,8-triaza-8-spiro[4.5]decanecarboxylate (4.7 g, 16.6 mmol), m.p. 206-208°C.

30

35

A mixture of *tert*-butyl 2,4-dioxo-3-methyl-1,3,8-triaza-8-spiro[4.5]decanecarboxylate (4.7 g, 16.6 mmol), hydrogen chloride (5 g, 13.7 mmol) and ethanol (90 ml) was heated approximately 10 minutes at reflux. The mixture was cooled in an ice-bath and the solids were collected, washed with ethanol and dried at 70°C to give 3-methyl-1,3,8-triaza-spiro[4.5]decane-2,4-dione hydrochloride (3.5 g, 15.9 mmol).

Proceeding similarly but with different starting materials gave *N*-[3-(2,4-dioxo-1,3,8-triazaspiro[4.5]decan-3-yl)propyl]-4-methoxybenzenesulfonamide as the trifluoroacetate salt.

EXAMPLE 19A

3-(1-Methylethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione

The following is the preparation of a compound of Formula 2 in which X is NH, Y is C(O), Z is C(O) and R³ is isopropyl.

A mixture of *tert*-butyl 2,4-dioxo-1,3,8-triaza-8-spiro[4.5]decane-carboxylate (4.18 g, 15.5 mmol), 60% sodium hydride in oil (0.68 g, 17 mmol), and DMF (25 ml) was stirred approximately one hour at 25°C; then 2-iodopropane (2.7 g, 16 mmol) was added and stirring was continued for three days. The solvent was removed under reduced pressure, and the residue was stirred with water (80 ml) for a few minutes. The insoluble solid was collected and purified by chromatography, eluting with ethyl acetate/hexane (60:40). *tert*-Butyl 2,4-dioxo-3-(1-methylethyl)-1,3,8-triaza-8-spiro[4.5]decanecarboxylate (0.66 g, 2.1 mmol), m.p. 206-208°C, was obtained as fine needles.

The *tert*-butyl 2,4-dioxo-3-(1-methylethyl)-1,3,8-triaza-8-spiro[4.5]decanecarboxylate was deprotected in the manner described in Example 19 to give 3-(1-methylethyl)-

1,3,8-triazaspiro[4.5]decane-2,4-dione as the hydrochloride salt, m.p. >285°C.

EXAMPLE 19B

5

3-(2,3-Dihydroxypropyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione

The following is the preparation of a compound of Formula 2 in which X is NH, Y is C(O), Z is C(O) and R³ is 2,3-
10 dihydroxypropyl.

A mixture of *tert*-butyl 2,4-dioxo-1,3,8-triaza-8-spiro[4.5]decane-carboxylate (6.9 g, 25.6 mmol), 3-bromo-1,2-propanediol (4.4 g, 28 mmol), sodium iodide (1.5 g, 10
15 mmol), potassium carbonate (14 g) and DMF (25 ml) was stirred approximately 48 hours at 100°C. Additional 3-bromo-1,2-propanediol (1.5 g, 10 mmol) was added, and the stirring and heating continued for an additional 72 hours. After cooling, the mixture was filtered, the solvent removed from the
20 filtrate under vacuum, and the residue was purified by chromatography eluting with ethyl acetate containing 0.5-1% acetic acid. The fractions containing the product were combined and concentrated, and the residue was treated with ethyl acetate to give *tert*-butyl 2,4-dioxo-3-(2,3-
25 dihydroxypropyl)-1,3,8-triaza-8-spiro[4.5]decanecarboxylate (1.5 g, 4.4 mmol) as a white solid, m.p. 167-170°C.

The *tert*-butyl 2,4-dioxo-3-(2,3-dihydroxypropyl)-1,3,8-triaza-8-spiro[4.5]decanecarboxylate was deprotected in
30 the manner described in Example 19 to give 3-(2,3-dihydroxypropyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione as the hydrochloride salt, m.p. 255-256°C.

3-(2,3-Dihydroxypropyl)-1,3,8-triazaspiro[4.5]decane-
35 2,4-dione may also be prepared by reaction of *tert*-butyl 2,4-dioxo-1,3,8-triaza-8-spiro[4.5]decanecarboxylate with an

epihalohydrin to give tert-butyl 2,4-dioxo-3-(2,3-epoxy-propyl)-1,3,8-triaza-8-spiro[4.5]decanecarboxylate, followed by hydrolysis of the epoxy group and deprotection.

- 5 Proceeding in a similar manner, using 2-iodoethanol, there was obtained 3-(2-hydroxyethyl)-1,3,8-triazaspiro[4.5]-decane-2,4-dione as the hydrochloride salt, m.p. 267-269°C.

- 10 Proceeding in a similar manner, using 3-(4-fluorophenyl)-propyl methanesulfonate, there was obtained 3-(4-fluorophenyl)propyl-1,3,8-triazaspiro[4.5]decane-2,4-dione as the hydrochloride salt, m.p. 279-283°C.

- 15 Other 3-substituted 1,3,8-triazaspiro[4.5]decane-2,4-diones may be prepared using the methods described.

EXAMPLE 20

- 20 4-Amino-1-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]piperidine-4-carbonitrile

The following is the preparation of a compound of Formula 14 in which n is 4, t is 1, u is 1, R¹ is chloro at the β-position and R² is methoxy.

- 25 A mixture of 1-[5-(5-chloro-2-methoxyphenyl)-5,5-ethylenedioxy-pentyl]-4-piperidone (6.62 g, 18 mmol), potassium cyanide (1.4 g, 35.8 mmol), ammonium chloride (2.46 g, 37 mmol), ammonium hydroxide (14 M, 4 ml, 56 mmol), water (25 ml) and methanol (120 ml) was heated 2 hours with stirring at
30 approximately 25°C and then 5 hours at 60°C. The mixture was concentrated and the residue was dissolved in ethyl acetate. The solution was washed with water (3x) and brine (1x), dried (MgSO₄) and concentrated to give 4-amino-1-[5-(5-chloro-
35 2-methoxyphenyl)-5,5-ethylenedioxy-pentyl]piperidine-4-carbonitrile (5.2 g, 13.1 mmol).

EXAMPLE 21

5 4-Amino-1-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]piperidine-4-carboxamide

The following is the preparation of a compound of Formula 16 in which n is 4, t is 1, u is 1, R¹ is chloro at the β-position and R² is methoxy.

10

A mixture of 4-amino-1-[5-(5-chloro-2-methoxyphenyl)-5,5-ethylenedioxy-pentyl]piperidine-4-carbonitrile (5.2 g, 13.1 mmol), prepared as in Example 20, water (1.6 ml) and sulfuric acid (41 ml) was warmed approximately 5 minutes on a steam bath and then cooled to 0°C and diluted with water (150 ml). The mixture was washed with ethyl acetate (2x), cooled to 0°C, treated with potassium hydroxide, filtered, washed with chloroform and extracted with methylene chloride (4x). The combined extracts were dried (MgSO₄) and concentrated. The residue was recrystallized from ethyl acetate/hexane to give 4-amino-1-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]piperidine-4-carboxamide (4.2 g, 11.4 mmol). Free base (135 mg, 0.367 mmol) was recrystallized from a solution of hydrogen chloride in ethanol to give 4-amino-1-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]piperidine-4-carboxamide hydrochloride (65 mg, 0.16 mmol).

20

25

EXAMPLE 22

30

8-[5-(5-Chloro-2-methoxyphenyl)-5-oxopentyl]-2-thioxo-1,3,8-triazaspiro[4.5]decane-4-one

The following is the preparation of a compound of Formula I in which n is 4, t is 1, u is 1, X is NH, Y is C(O), Z is

35

C(S), R¹ is chloro at the β -position, R² is methoxy and R³ is hydro.

A mixture of 4-amino-1-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]-piperidine-4-carboxamide (0.36 g, 1 mmol), prepared as in Example 21, 1,1'-thiocarbonyldiimidazole (0.23 g, 1.3 mmol), and DMF (3 ml) was heated 5 hours at 50-60°C and then diluted with water. The mixture was extracted with ethyl acetate and the extract was dried (MgSO₄) and concentrated. The residue was purified by column chromatography eluting with methylene chloride/methanol+ammonium hydroxide (95:5) to give 8-[5-(5-chloro-2-methoxy-phenyl)-5-oxopentyl]-2-thioxo-1,3,8-triazaspiro[4.5]decane-4-one (0.12 g, 0.29 mmol), m.p. 152-154°C (dec).

EXAMPLE 23

N-[5-[5-(2,4-Dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl]-4-trifluoromethylbenzenesulfonamide

The following is the preparation of a compound of Formula I in which n is 4, t is 2, u is 1, X is NH, Y is C(O), Z is C(O), R¹ is 4-trifluoromethyl-phenylsulfonylamino and methoxy at the β - and γ -positions, respectively, R² is methoxy and R³ is hydro.

A mixture of N-[5-(5-chloropentanoyl)-2,4-dimethoxyphenyl]-4-trifluoro-methylbenzenesulfonamide (0.8 g, 1.7 mmol), prepared as in Example 14, 1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride (0.55 g, 2.7 mmol), prepared as in Example 16, sodium iodide (0.4 g, 2.7 mmol), triethylamine (0.5 g, 5 mmol) in DMF (approximately 5 ml) was heated 16 hours at 115°C. The mixture was concentrated and the residue was stirred with water and the solids were collected, dried and purified by column chromatography eluting with methylene

chloride/methanol+ammonium hydroxide (95:5) to give
N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
2,4-dimethoxy-phenyl}-4-trifluoromethylbenzenesulfonamide
(0.4 g, 0.65 mmol), m.p. 226°C. The free base was
5 recrystallized from a solution of hydrogen chloride in ethanol
to give N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-
pentanoyl]-2,4-dimethoxyphenyl}-4-trifluoromethylbenzene-
sulfonamide hydrochloride (0.37 g, 0.57 mmol),
m.p. 277-278°C (dec).

10

Proceeding similarly as in Example 23 with different
starting materials gave the following compounds of Formula I
or protected derivatives thereof:

- 15 3-methyl-8-[5-oxo-5-(2,4,5-trimethoxyphenyl)pentyl]-
1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
m.p. 269-270°C;
3-(4-fluorophenyl)propyl-8-[5-oxo-5-(4-chloro-2,6-dimethoxy-
phenyl)pentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione
20 hydrochloride, m.p. 233-235°C;
8-[5-(4-methoxybiphenyl-3-yl)-5-oxopentyl]-1,3,8-triazaspiro-
[4.5]decane-2,4-dione hydrochloride, m.p. 198-200°C;
8-[5-(2-methoxynaphthalen-1-yl)-5-oxopentyl]-
1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
25 m.p. 162-173°C;
8-[5-(5-chloro-2,4-dimethoxyphenyl)5-oxopentyl]-1,3,8-triaza-
spiro[4.5]decane-2,4-dione hydrochloride, m.p. 164-166°C;
8-[6-(5-chloro-2-methoxyphenyl)-6-oxohexyl]-1,3,8-triaza-
spiro[4.5]decane-2,4-dione hydrochloride, m.p. 144-148°C;
30 8-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]-3-methyl-
1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
m.p. 260-263°C;
3,8-di[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]-
1,3,8-triazaspiro[4.5]decane-2,4-dione maleate,
35 m.p. 122-123°C;

- 8-[5-(2,5-dimethoxyphenyl)-5-oxopentyl]-
1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
m.p. 245-246°C;
- 8-[5-(3-methoxynaphthalen-2-yl)-5-oxopentyl]-
5 1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
m.p. 254-255°C;
- 3-tert-butyl-8-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]-
1-oxa-3,8-diazaspiro[4.5]decane-2-one hydrochloride,
m.p. 238-239°C;
- 10 8-[5-(6-methoxynaphthalen-2-yl)-5-oxopentyl]-1,3,8-triaza-
spiro[4.5]decane-2,4-dione hydrochloride, m.p. 167°C (eff);
8-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]-1-oxa-3,8-diaza-
spiro[4.5]decane-2,4-dione hydrochloride, m.p. 168-178°C;
- 15 8-[5-oxo-5-(2,4,5-trimethoxyphenyl)pentyl]-1,3,8-triaza-
spiro[4.5]decane-2,4-dione hydrochloride, m.p. 255-256°C;
- 8-[5-(4-amino-5-chloro-2-methoxyphenyl)-5-oxopentyl]-
1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
m.p. 167°C;
- 8-[5-(3,5-dichloro-2-methoxyphenyl)-5-oxopentyl]-
20 1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
m.p. 219-220°C;
- 8-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]-1-phenyl-
1,3,8-triazaspiro[4.5]decane-4-one hydrochloride,
m.p. 245-247°C;
- 25 N-(3-{8-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]-2,4-dioxo-
1,3,8-triazaspiro[4.5]dec-3-yl}propyl-4-methoxybenzenesulfon-
amide hydrochloride, m.p. 198-199°C;
- 1,3-dimethyl-8-[5-oxo-5-(2,4,5-trimethoxyphenyl)pentyl]-
1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
30 m.p. 245-246°C;
- 8-[5-(4-chloro-2-methoxyphenyl)-5-oxopentyl]-
1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
m.p. >130°C;
- 8-[5-(2,5-dichlorophenyl)-5-oxopentyl]-1,3,8-triazaspiro-
35 [4.5]decane-2,4-dione hydrochloride, m.p. 213-215°C;

- 8-[5-(6-bromo-2-methoxynaphthalen-1-yl)-5-oxopentyl]-
1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
m.p. 174-176°C;
- 8-[5-(2-benzyloxy-5-chlorophenyl)-5-oxopentyl]-1,3,8-triaza-
5 spiro[4.5]decane-2,4-dione hydrochloride, m.p. 141-144°C;
- 8-[5-(2-methoxy-4,5-methylenedioxyphenyl)-5-oxopentyl]-
1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
m.p. 188-191°C;
- 8-[5-(5-chloro-2-ethoxyphenyl)-5-oxopentyl]-1,3,8-triaza-
10 spiro[4.5]decane-2,4-dione hydrochloride, m.p. 147°C (dec);
- 8-[5-(2-methoxy-5-nitrophenyl)-5-oxopentyl]-1,3,8-triazaspiro-
[4.5]decane-2,4-dione hydrochloride, m.p. 244-245°C;
- 8-[5-(5-amino-2-methoxyphenyl)-5-oxopentyl]-1,3,8-triazaspiro-
[4.5]decane-2,4-dione hydrochloride, m.p. >200°C (dec);
- 15 8-[4-(5-chloro-2-methoxyphenyl)-4-oxobutyl]-3-methyl-
1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride,
m.p. 283-284°C;
- 8-[4-(5-chloro-2-methoxyphenyl)-4-oxobutyl]-1,3,8-triazaspiro-
[4.5]decane-2,4-dione hydrochloride, m.p. 244-246°C;
- 20 8-[4-(5-chloro-2-hydroxyphenyl)-4-oxobutyl]-1,3,8-triazaspiro-
[4.5]decane-2,4-dione hydrochloride, m.p. 208-211°C;
- 8-[6-(4-methoxybiphenyl-3-yl)-6-oxohexyl]-3-methyl-
1,3,8-triaza-spiro[4.5]decane-2,4-dione hydrochloride,
m.p. 235-238°C;
- 25 8-[5-(2-methoxy-5-phenoxyphenyl)-5-oxopentyl]-1,3,8-triaza-
spiro[4.5]decane-2,4-dione hydrochloride, m.p. 168-170°C;
- 8-[5-(2,4-dimethoxy-5-nitrophenyl)-5-oxopentyl]-1,3,8-triaza-
spiro[4.5]decane-2,4-dione hydrochloride, m.p. 215-216°C;
- N-(2-{8-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]-2,4-dioxo-
30 1,3,8-triazaspiro[4.5]dec-3-yl}ethyl)methanesulfonamide
hydrochloride, m.p. >120°C;
- N-{3-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
4-methoxyphenyl}benzamide hydrochloride, m.p. 205-208°C;
- N-{3-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
35 4-methoxyphenyl}-2-chlorobenzamide hydrochloride, m.p. >170°C;

- N*-(4-[2-chloro-5-(2,4-dioxo-3-methyl-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-5-methoxyphenyl)acetamide hydrochloride, m.p. 182-184°C;
- N*-(3-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-4-methoxyphenyl)acetamide hydrochloride, m.p. 249-250°C;
- N*-(3-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-4-methoxyphenyl)-4-chlorobenzenesulfonamide hydrochloride, m.p. 215-218°C;
- 8-[5-(2,3-ethylenedioxyphenyl)-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride, m.p. 170-175°C (dec);
- 8-[5-(5,6-dichloro-2,3-ethylenedioxyphenyl)-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride, m.p. 282-284°C (dec);
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)benzenesulfonamide hydrochloride, m.p. 191-193°C;
- 8-[5-(5,6-dichloro-2-methoxyphenyl)-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride, m.p. 167-170°C;
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)naphthalen-1-ylsulfonamide, m.p. 147-150°C;
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-1-piperidinesulfonamide hydrochloride, m.p. 213-215°C;
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)methanesulfonamide hydrochloride, m.p. 256-257°C;
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-4-chlorobenzenesulfonamide hydrochloride, m.p. 258-260°C;
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-4-nitrobenzenesulfonamide hydrochloride, m.p. 261-262°C;

- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-4-toluenesulfonamide hydrochloride, m.p. 266°C;
- 5 *N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-2,4-difluorobenzenesulfonamide hydrochloride, m.p. >170°C (dec); .
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-3-chlorobenzenesulfonamide hydrochloride, m.p. 170-173°C;
- 10 *N*-(5-[5-(3-(1-methylethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-4-trifluoromethylbenzenesulfonamide hydrochloride, m.p. 205-206°C;
- N*-(5-[5-(3-(2-hydroxyethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-4-trifluoro-
- 15 methylbenzenesulfonamide hydrochloride, m.p. 205-208°C;
- N*-(5-[5-(3-(2,3-dihydroxypropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-4-trifluoromethylbenzenesulfonamide, m.p. 161-163°C;
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4,6-trimethoxyphenyl)-4-trifluoromethylbenzenesulfonamide
- 20 hydrochloride, m.p. 261-263°C;
- N*-(5-[5-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-pentanoyl]-2,4,6-trimethoxyphenyl)-4-trifluoromethylbenzenesulfonamide hydrochloride, m.p. 190°C;
- 25 *N*-(5-[5-(3-(4-fluorophenyl)propyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4,6-trimethoxyphenyl)-4-trifluoromethylbenzenesulfonamide hydrochloride, m.p. 205-207°C;
- 1-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-3-(3-trifluoromethylphenyl)urea
- 30 hydrochloride, m.p. 213°C;
- 1-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-3-(4-trifluoromethylphenyl)urea hydrochloride, m.p. 202-225°C;

- 1-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
2,4-dimethoxyphenyl}-3-(2-trifluoromethylphenyl)urea
hydrochloride, m.p. 200°C (eff);
- 1-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
5 2,4-dimethoxyphenyl}-3-prop-2-ylurea hydrochloride,
m.p. 190-198°C (eff);
- N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
2,4-dimethoxyphenyl}-4-trifluoromethoxybenzenesulfonamide
hydrochloride, m.p. 265°C (dec);
- 10 N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
2,4-dimethoxyphenyl}-2-chlorobenzenesulfonamide hydrochloride,
m.p. 174-200°C;
- N-(4-{5-[5-(2,4-dioxo-
1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl}-
15 sulfamoyl)phenyl)acetamide hydrochloride, m.p. 220-224°C;
- N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
2,4-dimethoxyphenyl}-4-prop-2-ylbenzenesulfonamide
hydrochloride, m.p. >280°C;
- N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
20 2,4-dimethoxyphenyl}-2-thiophenesulfonamide hydrochloride,
m.p. 169-171°C;
- N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
2,4-dimethoxyphenyl}-2-naphthalenesulfonamide hydrochloride,
m.p. 254-255°C;
- 25 N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
2,4-dimethoxyphenyl}-5-chloro-2-thiophenesulfonamide
hydrochloride, m.p. 228-230°C;
- N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
2,4-dimethoxyphenyl}-4-methoxybenzenesulfonamide
30 hydrochloride, m.p. 252-253°C;
- N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
2,4-dimethoxyphenyl}-4-pyridinecarboxamide hydrochloride,
m.p. 232-235°C;
- N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
35 2,4-dimethoxyphenyl}-2-(5-trifluoromethylpyrid-2-ylsulfonyl)-
4-thiophenesulfonamide hydrochloride, m.p. 186-192°C;

- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-5-(5-trifluoromethylpyrid-2-ylsulfonyl)-2-thiophenesulfonamide hydrochloride, m.p. 183-189°C;
- 5 *N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-3,5-ditrifluoromethylbenzenesulfonamide hydrochloride, m.p. 157-164°C;
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-5-pyrid-2-yl-2-thiophenesulfonamide hydrochloride, m.p. 178-185°C;
- 10 *N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-3-trifluoromethylbenzenesulfonamide hydrochloride, m.p. 178-181°C;
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-3,4-difluorobenzenesulfonamide
- 15 hydrochloride, m.p. 229-230°C;
- 8-[5-(4-amino-2,5-dimethoxyphenyl)-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride, m.p. 182-190°C;
- 8-[7-(5-chloro-2-methoxyphenyl)-7-oxoheptyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride, m.p. 168-170°C;
- 20 *N*-(5-[5-(2,4-dioxo-3-methyl-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-4-cyanobenzenesulfonamide maleate, m.p. 113-120°C;
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-4-cyanobenzenesulfonamide maleate,
- 25 m.p. 230-235°C;
- N*-(5-[5-(2,4-dioxo-3-methyl-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-4-trifluoromethylbenzenesulfonamide hydrochloride, m.p. 181-182°C;
- 30 *N*-(5-[6-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)hexanoyl]-2,4-dimethoxyphenyl)-4-trifluoromethylbenzenesulfonamide hydrochloride, m.p. 177-180°C;
- N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl)-4-trifluoromethylbenzamide
- 35 hydrochloride, m.p. 245-248°C;

8-[5,5-ethylenedioxy-5-(5-chloro-2-methoxyphenyl)pentyl]-
1,3,8-triaza-spiro[4.5]decane-2,4-dione, m.p. 154-155°C;
N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-1,1-
ethylenedioxy-pentyl]-3,4-ethylenedioxyphenyl}-
5 4-trifluoromethylbenzenesulfonamide;
8-[4-(5-chloro-2-methoxyphenyl)-4,4-ethylenedioxybutyl]-
1,3,8-triaza-spiro[4.5]decane-2,4-dione;
N-{4-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
2,5-dimethoxyphenyl}-4-chlorobenzenesulfonamide, m.p. >170°C;
10 8-[5-(2,4-dimethoxyphenyl)-5-oxopentyl]-1,3,8-triazaspiro-
[4.5]decane-2,4-dione hydrochloride, m.p. 200-202°C; and
8-[5-(2,4,5-trimethoxyphenyl)-5-oxopentyl]-1,3,8-triazaspiro-
[4.5]decane-2,4-dione, m.p. 220-222°C.

15

EXAMPLE 24

8-[5-(5-Chloro-2-methoxyphenyl)-5-oxopentyl]-1,3,8-triaza-
spiro[4.5]decane-2,4-dione

20 The following is the preparation of a compound of Formula
I in which n is 4, t is 1, u is 1, X is NH, Y is C(O), Z is
C(O), R¹ is chloro at the β-position, R² is methoxy and R³ is
hydro.

25 A mixture of 8-[5,5-ethylenedioxy-5-(5-chloro-
2-methoxyphenyl)pentyl]-1,3,8-triaza-
spiro[4.5]decane-2,4-dione (1-1.1 g, 2.3-2.6 mmol), prepared
as in Example 23, 10% hydrochloric acid (approximately 1 ml)
and methanol (approximately 30 ml) was heated to a boil and
30 then allowed to cool and stand approximately 4 hour at 25°C.
The solids were collected and dried under vacuum at 70°C to
give 8-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]-
1,3,8-triaza-spiro[4.5]decane-2,4-dione hydrochloride (0.37 g,
0.57 mmol), m.p. 260-262°C.

35

Proceeding similarly as in Example 24 with different starting materials gave the following compounds of Formula I:

N-{3-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-4,5-ethylenedioxyphenyl}-4-trifluoromethylbenzenesulfonamide hydrochloride, m.p. 261-262°C; and
8-[4-(5-chloro-2-methoxyphenyl)-4-oxobutyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione.

10

EXAMPLE 25

8-[5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione

15 The following is the preparation of a compound of Formula I in which *n* is 4, *t* is 2, *u* is 1, *X* is NH, *Y* is C(O), *Z* is C(O), *R*¹ is amino and methoxy at the β- and γ-positions, respectively, *R*² is methoxy and *R*³ is hydro.

20 A mixture of 8-[5-(2,4-dimethoxy-5-nitrophenyl)-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione (0.33 g, 0.76 mmol), prepared as in Example 23, 10% palladium on carbon (140 mg in 5 ml of water), THF (50 ml) and ethanol (50 ml) was stirred 2 hours under a hydrogen atmosphere (15 psi). The
25 mixture was filtered and concentrated to give 8-[5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride, m.p. 245°C (dec).

30 Proceeding similarly as in Example 25 with different starting materials gave the following compounds of Formula I:

8-[5-(5-amino-2-methoxyphenyl)-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione, m.p. 211-213°C; and
N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl}-4-aminobenzenesulfonamide hydrochloride,
35 m.p. 206-208°C.

EXAMPLE 26

1-{5-[5-(2,4-Dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
5 2,4-dimethoxyphenyl}-3-(3-trifluoromethylphenyl)thiourea

The following is the preparation of a compound of Formula
I in which n is 4, t is 2, u is 1, X is NH, Y is C(O), Z is
C(O), R¹ is 3-trifluoromethyl-thioureido and methoxy at the β-
10 and γ-positions, respectively, R² is methoxy and R³ is hydro.

A mixture of 8-[5-(5-amino-2,4-dimethoxyphenyl)-
5-oxopentyl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione (62 mg,
0.15 mmol), prepared as in Example 21, a,a,a-trifluoro-m-tolyl
15 isothiocyanate (1.335 g/ml, 0.03 ml, 0.17 mmol) and N-methyl-
2-pyrrolidinone was stirred 10 minutes. The mixture was added
to water (50 ml) and the solids were collected, washed with
water, dried and recrystallized from a solution of hydrogen
chloride in ethanol/ether to give 1-{5-[5-(2,4-dioxo-
20 1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxy-
phenyl}-3-(3-trifluoromethylphenyl)thiourea hydrochloride (40
mg, 0.06 mmol), m.p. 159-168°C.

EXAMPLE 27

25

N-{5-[5-(2,4-Dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-
2,4-dimethoxy-phenyl}-3-(5-trifluoromethyl-1-
methylpyrazol-3-yl)-2-thiophenesulfonamide

30

The following is the preparation of a compound of Formula
I in which n is 4, t is 2, u is 1, X is NH, Y is C(O), Z is
C(O), R¹ is 3-(5-trifluoro-methyl-1-methylpyrazol-3-yl)thien-
2-ylsulfonylamino and methoxy at the β- and γ-positions,
respectively, R² is methoxy and R³ is hydro.

35

A mixture of 8-[5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione (202 mg, 0.5 mmol), prepared as in Example 21, 3-(5-trifluoromethyl-1-methylpyrazol-3-yl)-2-thiophenesulfonyl chloride (200 mg, 0.6 mmol) and THF (1 ml) and *N*-methyl-2-pyrrolidinone (1 ml) was stirred 16 hours at approximately 25°C. The mixture was purified by flash chromatography eluting first with methylene chloride and then with methylene chloride/methanol+ammonium hydroxide (9:1). The purified product was recrystallized from ethanol and then from a solution of hydrogen chloride in ethanol/ether to give *N*-(5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-pentanoyl]-2,4-dimethoxyphenyl)-3-(5-trifluoromethyl-1-methylpyrazol-3-yl)-2-thiophenesulfonamide hydrochloride (94 mg, 0.13 mmol), m.p. 162-170°C.

15

Proceeding similarly as in Example 27 with different starting materials the following compounds of Formula I were prepared:

- 20 *N*-(3-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-4-methoxyphenyl)-1-pyrrolidinesulfonamide hydrochloride, m.p. 227-229°C;
N-(3-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-4-methoxyphenyl)benzenesulfonamide hydrochloride,
25 m.p. 170-182°C;
N-(3-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-4-methoxyphenyl)-3,4-dimethoxybenzenesulfonamide hydrochloride, m.p. 150-167°C; and
4-[5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxy-phenylsulfamoyl]benzenesulfonamide,
30 m.p. 270-272°C

EXAMPLE 28

8-[5-(5-Chloro-2-methoxyphenyl)-
5-oxopentyl]-1-oxa-3,8-diazaspiro[4.5]decane-2-one

5

The following is the preparation of a compound of Formula I in which n is 4, t is 1, u is 1, X is O, Y is CH, Z is C(O), R¹ is chloro at the β-position, R² is methoxy and R³ is hydro.

10 A mixture of 3-tert-butyl-8-[5-(5-chloro-2-methoxy-phenyl)-5-oxopentyl]-1-oxa-3,8-triazaspiro[4.5]decane-2-one (200 mg, 0.46 mmol), prepared as in Example 23, trifluoroacetic acid (5 ml) and water (2 ml) was heated 6 days at reflux and then concentrated to 2 ml. The residue was
15 combined with water and the mixture was treated with sodium bicarbonate and then extracted with methylene chloride. The product was purified by column chromatography eluting with methylenechloride/ methanol+ammonium hydroxide (20:1) to give
20 8-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]-1-oxa-3,8-triazaspiro[4.5]decane-2-one (50 mg, 0.13 mmol). The free base was recrystallized from a solution of hydrogen chloride in ethanol/ether to give 8-[5-(5-chloro-2-methoxyphenyl)-5-oxopentyl]-1-oxa-3,8-triazaspiro[4.5]decane-2-one hydrochloride, m.p. 130-134°C.

25

EXAMPLE 29

The following are representative pharmaceutical formulations containing a compound of Formula I.

30

ORAL FORMULATION

A representative solution for oral administration contains:

35

	Compound of Formula I	100-1000 mg
	Citric Acid Monohydrate	105 mg
	Sodium Hydroxide	18 mg
	Flavoring	
5	Water	q.s. to 100 ml

INTRAVENOUS FORMULATION

A representative solution for intravenous administration
10 contains:

	Compound of Formula I	10-100 mg
	Dextrose Monohydrate	q.s. to make isotonic
	Citric Acid Monohydrate	1.05 mg
15	Sodium Hydroxide	0.18 mg
	Water for Injection	q.s. to 1.0 ml

TABLET FORMULATION

20 A representative tablet form of a compound of Formula I
may contain:

	Compound of Formula I	1%
	Microcrystalline Cellulose	73%
25	Stearic Acid	25%
	Colloidal Silica	1%

Cloned Rat 5-HT_{2C} Receptor Binding Assay

30

The following describes an *in vitro* binding assay
utilizing cloned 5-HT_{2C} receptors radiolabelled with
[³H]mesulergine.

35 Mouse NIH3T3 fibroblasts expressing a cloned rat 5-HT_{2C}
receptor were maintained in Dulbecco's Modified Eagle medium

with 10% Fetal Calf Serum and 250 µg/ml G418 in 95/5% O₂/CO₂. The cells were harvested using 2 mM EDTA in phosphate buffered saline (calcium/magnesium free) and centrifuged (500 g). The cell pellet was homogenized using a Polytron P10 disrupter
5 (setting 5, 5 sec) in homogenization buffer (Tris, 50 mM; Na₂EDTA, 5 mM) and the homogenate was centrifuged at 19,500 rpm using a Sorvall/Dupont RC5C centrifuge with an SS34 rotor (30,000-48,000 g, 15 minutes). The pellet was homogenized (setting 5, 5 sec) in homogenization buffer and
10 the homogenate was centrifuged (30,000-48,000 g, 15 minutes). The pellet was homogenized (setting 5, 5 sec) in resuspension buffer (Tris, 50 mM; EDTA 0.5 mM) and the homogenate was centrifuged (30,000-48,000 g, 15 minutes). The pellet was homogenized (setting 5, 5 sec) in a small volume of
15 resuspension buffer to give approximately 1x10⁷ cells/ml. The membranes were separated into 1 ml aliquots and stored at -70°C.

The membranes were thawed at room temperature and diluted
20 with assay buffer (NaCl, 118 mM; KCl, 4.5 mM; KH₂PO₄, 1.2 mM; CaCl₂·2H₂O, 2.5 mM; MgCl₂, 1 mM; D-glucose, 10 mM; Tris, 25 mM). An optimal dilution ratio was predetermined for each batch of membranes to ensure that less than 10% of 5x10⁻¹⁰M [³H]mesulergine binds, specific binding is at least
25 10 times greater than a machine background of 23 dpm and the best ratio of specific binding to total binding is achieved. The membranes were homogenized (setting 5, 5 sec) and then added to assay tubes containing mesulergine (5x10⁻¹⁰M), test compound (1x10⁻¹⁰-1x10⁻⁴M) and assay buffer (q.s. to 500 µL).
30 The assay mixture was incubated at 32°C for 60 minutes and then filtered over 0.1% polyethyleneimine pretreated glass fiber filtermats using a Brandel cell harvester. The assay tubes were rinsed with cold 0.1 M sodium chloride (3x 3 sec) and dried by drawing air over the filter for 10 seconds.
35 Radioactivity retained on the filters was determined by liquid scintillation counting. In a similar fashion, total binding

was measured with methysergide ($1 \times 10^{-5} \text{M}$) in the absence of test compound. For each compound tested the concentration producing 50% inhibition of binding (IC_{50}) was determined using iterative curve fitting techniques.

5

Proceeding as in Example 30, compounds of the invention were tested and found to have affinity for the 5-HT_{2C} receptor.

10

EXAMPLE 31

Cloned Rat 5-HT_{2C} Receptor Functional Assay

The following describes an *in vitro* functional assay
15 utilizing 5-HT induced, 5-HT_{2C} mediated increases in NIH3T3 cellular metabolic activity.

Mouse NIH3T3 fibroblasts expressing cloned 5-HT_{2C} receptor were maintained in high glucose Dulbecco's Minimal
20 Essential Medium (DMEM) further comprising glutamine, sodium pyruvate and 10% Fetal Bovine. The cells were harvested using 2 mM EDTA in phosphate buffered saline and transferred to 6.5 mm transwell capsule plates (3 micron pore size) to give approximately 1×10^5 cells/capsule. The cells were allowed to
25 adhere overnight and then transwell spacers and inserts were added to each transwell capsule. The capsules were placed into sensor chambers and the sensor chambers were loaded onto a microphysiometer.

30 The 5-HT_{2C} receptor antagonist properties of test compounds were appraised by determining their affect on 5-HT induced increases in cellular metabolic activity, expressed as percent increase in acidification rate. Microphysiometer Running Medium (high glucose, sodium bicarbonate free DMEM)
35 was pump through the transwell capsules for 1.5 minutes, 30 seconds of which 5-HT was present in the medium, followed by a

45 minute washout and recovery period. In this manner, cells were exposed to 5-HT in a non-cumulative concentration fashion, increasing in concentration until maximal or near maximal effect was observed.

5

Concentration-effect curves were constructed for 5-HT with and without the test compound present. Data was analyzed by iterative curve fitting techniques and the concentration ratio (CR) of 5-HT necessary to produce equiactive responses in the absence and presence of the test compound was determined. Relying on the concentration ratio, the molar concentration of the test compound, and the relationship:

$$pK_b = -\log \frac{[\text{test compound}]}{CR - 1}$$

15

the negative log of the dissociation constant (pK_b) for each test compound was determined.

Proceeding as in Example 31, compounds of the invention were tested and found to be antagonists at the 5-HT_{2C} receptor.

20

EXAMPLE 32

25

ANXIOLYTIC BEHAVIOR ASSAY

The following describes an *in vivo* method for determining anxiolytic activity by measuring the extent the drug affects the natural anxiety of mice when exposed to a novel, brightly lighted environment.

30

Naive male C5BI/6J mice, 18-20 g, are kept in groups of 10 mice in quarters controlled for sound, temperature and humidity. Food and water are available *ad libitum*. The mice are kept on a 12 hour light and 12 hour dark cycle, with

35

lights on at 6:00 a.m. and off at 6:00 p.m. All experiments begin at least 7 days after arrival on site.

The automated apparatus for detecting changes in exploration is obtained from Omni-Tech Electronics Columbus Ohio and is similar to that of Crawley and Goodwin (1980), as described in Kilfoil et al., cited previously. Briefly, the chamber consists of a plexiglass box (44 x 21 x 21 cm), divided into two chambers by a black plexiglass partition. The partition dividing the two chambers contains a 13 x 5 cm opening through which the mouse can easily pass. The dark chamber has clear sides and a white floor. A fluorescent tube light (40 watt) placed above the chambers provides the only illumination. The Digiscan Animal Activity Monitor System RXYZCM16 (Omni-Tech Electronics) records the exploratory activity of the mice within the test chambers.

Prior to commencement of the study the mice are given 60 min to acclimatize to the laboratory environment. After a mouse receives an intraperitoneal (i.p.) injection of either test compound or vehicle it is returned to its home cage for a 15 min post-treatment period. The mouse is then placed in the center of the light chamber and monitored for 10 minutes.

Anxiolytic behavior is seen as a general increase in exploratory activity in the lighted area. An increase in exploratory activity is reflected by increased latency (the time for the mouse to move to the dark chamber when first placed in the center of the lighted area), increase in shuttle activity, increased or unaltered locomotor activity (number of grid lines crossed) and decreased time spent in the dark compartment.

EXAMPLE 33

WITHDRAWAL ANXIETY ASSAY

5 The following describes an *in vivo* procedure for
determining amelioration of the symptoms caused by withdrawal
from addictive substances by measuring the extent the drug
affects the anxiety that occurs in mice after chronically
treating with an addictive substance and then abruptly ceasing
10 the treatments.

Naive male BKW mice (25-30 g) are caged in groups of ten
in quarters controlled for sound, temperature and humidity.
Food and water are available *ad libitum*. The mice are kept on
15 a 12 hour light cycle and 12 hour dark cycle, with lights on
at 6:00 a.m. and off at 6:00 p.m. All experiments begin at
least 7 days after arrival on site.


Levels of anxiety are determined by the two-compartment
20 exploratory model of Crawley and Goodwin (see Example 14).
Anxiolysis is seen as a general increase in exploratory
activity in the lighted area. An increase in exploratory
activity is reflected by increased latency (the time for the
mouse to move to the dark chamber when first placed in the
25 center of the lighted area), increased or unaltered locomotor
activity (number of grid lines crossed), increased number of
rears and decreased time spent in the dark compartment.

Increased exploratory activity in the lighted area is
30 induced by treating the mice for 14 days with ethanol (8.0 %
w/v in drinking water), nicotine (0.1 mg/kg, *i.p.*, twice
daily) or cocaine (1.0 mg/kg, *i.p.*, twice daily). Anxiolysis
is assessed 1, 3, 7 and 14 days after commencement of the drug
regime. The treatment is abruptly ceased and exploratory
35 activity in the lighted area is determined 8, 24 and 48 hours
thereafter. Vehicle or test compounds are administered during

the withdrawal phase by intraperitoneal injection. Responses are represented as inhibition of the decrease in anxiolytic behavior after the ethanol, cocaine or nicotine treatment is ceased.

Claims

1. A compound of Formula I:



I

in which:

n is 2, 3, 4, 5 or 6;

t is 1, 2, 3 or 4 and

10 u is 0 or 1 (provided that t is not 1 when u is 0);

X is O or N(R⁴), in which R⁴ is hydro, (C₁-₄)alkyl or aryl;

Y and Z are independently C(O), C(S) or CH₂ (provided that Y and Z are not both CH₂);

15 each

R¹ is independently amino, aryloxy, aryl(C₁-₄)alkyloxy, arylsulfonyl, arylthio, carbamoyl, cyano, halo, nitro, thiocarbamoyl, thioureido, ureido, a group selected from (C₁-₄)alkyl, (C₁-₄)alkyloxy and (C₁-₄)alkylthio (optionally further substituted with one to three halo atoms), a group selected from -NHSO₂R⁵, -NHC(O)R⁵, -NHC(O)NHR⁵, -NHC(S)NHR⁵ and -SO₂NHR⁵ (which R⁵ is (C₁-₄)alkyl (optionally further substituted with one to three halo atoms) or a group selected from aryl, aryl(C₁-₄)alkyl, heteroaryl and heteroaryl(C₁-₄)alkyl (optionally further substituted with one to two radicals independently selected from amino, carbamoyl, cyano, halo, nitro, a group selected from (C₁-₄)alkanoyl,

25 (C₁-₄)alkylsulfonylamino, (C₁-₄)alkanoylamino, (C₁-₄)alkyl and (C₁-₄)alkyloxy, optionally further substituted with one to three halo atoms, and a group selected from aryl, arylsulfonyl, heteroaryl and


heteroarylsulfonyl, optionally further substituted with one to two radicals independently selected from amino, cyano, halo, nitro and a group selected from (C₁₋₄)alkyl and (C₁₋₄)alkyloxy, optionally further substituted with one to three halo atoms}} or two adjacent R¹ substituents form ethylenedioxy, methylenedioxy or butadienylene (which butadienylene is optionally further substituted with one to two radicals selected from halo and (C₁₋₄)alkyloxy);

10 R² is hydroxy, halo, (C₁₋₄)alkyloxy or aryl(C₁₋₄)alkyloxy; and

R³ is hydro, (C₁₋₆)alkyl (optionally substituted with a group selected from -C(O)OH, -C(O)O(C₁₋₄)alkyl, -NHSO₂R⁵ and -NHC(O)R⁵, in which R⁵ is as defined above),

15 hydroxyalkyl, phenyl(C₁₋₄)alkyl (optionally substituted with one or two radicals independently selected from amino, cyano, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, acetamido, methanesulfonamido, (C₁₋₄)alkyl, or (C₁₋₄)alkyloxy), or a group of Formula (a):

20



wherein n, t and R¹ are as defined above; and the pharmaceutically acceptable salts and N-oxides

25 thereof.

2. The compound of Claim 1 in which n is 3, 4, 5 or 6; t is 2 or 3; u is 0; X is NH; Y is C(O) and Z is C(O) or C(S); two adjacent R¹ radicals form α,β-ethylenedioxy; a third R¹

30 radical, when present, is amino, phenyl, phenoxy, halo, nitro, ureido, thioureido, (C₁₋₄)alkyloxy or a group selected from -NHSO₂R⁵, -NHC(O)R⁵, -NHC(O)NHR⁵ and -NHC(S)NHR⁵ (which R⁵ is (C₁₋₄)alkyl or a group selected from optionally substituted

phenyl, optionally substituted naphthyl and optionally substituted thienyl}; and R^3 is hydro, (C_{1-6}) alkyl (optionally substituted with a group selected from $-C(O)OH$, $-C(O)O(C_{1-4})$ alkyl, $-NHSO_2R^5$ and $-NHC(O)R^5$, in which R^5 is as defined
5 above), hydroxyalkyl, or phenyl (C_{1-4}) alkyl (optionally substituted with one or two radicals independently selected from amino, cyano, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, acetamido, methanesulfonamido, (C_{1-4}) alkyl, or (C_{1-4}) alkyloxy).

10

3. The compound of Claim 1 in which n is 3, 4, 5 or 6; t is 1, 2 or 3; u is 1; X is NH ; Y is $C(O)$ and Z is $C(O)$ or $C(S)$; R^1 is amino, phenyl, phenoxy, halo, nitro, ureido, thioureido, (C_{1-4}) alkyloxy, a group selected from $-NHSO_2R^5$,
15 $-NHC(O)R^5$, $-NHC(O)NHR^5$ and $-NHC(S)NHR^5$ (which R^5 is (C_{1-4}) alkyl or a group selected from optionally substituted phenyl, optionally substituted naphthyl and optionally substituted thienyl} or with an adjacent R^1 radical form optionally substituted butadienylene; R^2 is (C_{1-4}) alkyloxy;
20 and R^3 is hydro, (C_{1-6}) alkyl (optionally substituted with a group selected from $-C(O)OH$, $-C(O)O(C_{1-4})$ alkyl, $-NHSO_2R^5$ and $-NHC(O)R^5$, in which R^5 is as defined above), hydroxyalkyl, or phenyl (C_{1-4}) alkyl (optionally substituted with one or two radicals independently selected from amino, cyano, halo,
25 hydroxy, nitro, trifluoromethyl, trifluoromethoxy, acetamido, methanesulfonamido, (C_{1-4}) alkyl, or (C_{1-4}) alkyloxy).

4. The compound of Claim 3 in which n is 4, 5 or 6; t is 1, 2, or 3; an R^1 radical is attached at the β - and/or
30 γ -positions, which R^1 radical when attached at the β -position is amino, phenoxy, chloro, nitro, (C_{1-4}) alkyloxy or $-NHSO_2R^5$ (which R^5 is a group selected from optionally substituted phenyl or optionally substituted thienyl} and when attached at the γ -position is chloro, (C_{1-4}) alkyloxy or amino; and R^2 is
35 methoxy.

5. The compound of Claim 4 in which n is 4; Z is C(O);
t is 2; one R¹ radical is attached at the β-position and is
phenylsulfonylamino (optionally further substituted with
amino, carbamoyl, cyano, chloro, fluoro, nitro or a group
5 selected from (C₁₋₄)alkanoyl, (C₁₋₄)alkylsulfonylamino,
(C₁₋₄)alkanoylamino, (C₁₋₄)alkyl and (C₁₋₄)alkyloxy,
optionally further substituted with one to three fluoro
atoms), and the other R¹ radical is attached at the γ-position
and is methoxy.
- 10 6. The compound of Claim 5 in which R¹ at the
β-position is 4-trifluoromethylphenylsulfonylamino.
- 15 7. The compound of Claim 6 in which R³ is hydro,
(C₁₋₆)alkyl, hydroxyalkyl, or phenyl(C₁₋₄)alkyl (where the
phenyl is optionally substituted with halo, hydroxy,
(C₁₋₄)alkyloxy, or trifluoromethyl).
- 20 8. The compound of Claim 7 which is N-{5-[5-(2,4-dioxo-
1,3,8-triaza-spiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxy-
phenyl}-4-trifluoromethylbenzenesulfonamide or a
pharmaceutically acceptable salt thereof.
- 25 9. The compound of Claim 7 which is N-{5-[5-(2,4-dioxo-
3-methyl-1,3,8-triaza-spiro[4.5]dec-8-yl)pentanoyl]-
2,4-dimethoxyphenyl}-4-trifluoromethylbenzenesulfonamide or a
pharmaceutically acceptable salt thereof.
- 30 10. The compound of Claim 4 in which n is 4; Z is C(O);
t is 2; one R¹ radical is attached at the γ-position and is
chloro, and the other R¹ radical is attached at the α-position
and is methoxy.
- 35 11. The compound of Claim 10 in which R³ is hydro,
(C₁₋₆)alkyl, hydroxyalkyl, or phenyl(C₁₋₄)alkyl (where the

phenyl is optionally substituted with halo, hydroxy, (C₁₋₄)alkyloxy, or trifluoromethyl}.

12. The compound of Claim 11 which is 8-[5-(4-chloro-
5 2,6-dimethoxyphenyl)-5-oxopentyl]-
3-(3-(4-fluorophenyl)propyl)-1,3,8-triazaspiro[4.5]decane-
2,4-dione or a pharmaceutically acceptable salt thereof.

13. The compound of Claim 4 in which n is 4; Z is C(O);
10 t is 3; one R¹ radical is attached at the β-position and is
phenylsulfonylamino (optionally further substituted with
amino, carbamoyl, cyano, chloro, fluoro, nitro or a group
selected from (C₁₋₄)alkanoyl, (C₁₋₄)alkylsulfonylamino,
(C₁₋₄)alkanoylamino, (C₁₋₄)alkyl and (C₁₋₄)alkyloxy,
15 optionally further substituted with one to three fluoro
atoms), and the other R¹ radicals are attached at the α- and
γ-positions and are both methoxy.

14. The compound of Claim 13 in which R¹ at the
20 β-position is 4-trifluoromethylphenylsulfonylamino.


15. The compound of Claim 14 in which R³ is hydro, (C<sub>1-
6</sub>)alkyl, hydroxyalkyl, or phenyl(C₁₋₄)alkyl (where the phenyl
is optionally substituted with halo, hydroxy, (C₁₋₄)alkyloxy,
25 or trifluoromethyl).

16. The compound of Claim 15 which is N-{5-[5-(2,4-
dioxo-1,3,8-triaza-spiro[4.5]dec-8-yl)pentanoyl]-2,4,6-
trimethoxyphenyl}-4-trifluoromethylbenzenesulfonamide or a
30 pharmaceutically acceptable salt thereof.

17. The compound of Claim 16 which is N-{5-[5-(2,4-
dioxo-3-methyl-1,3,8-triaza-spiro[4.5]dec-8-yl)pentanoyl]-
2,4,6-trimethoxyphenyl}-4-trifluoromethylbenzenesulfonamide or
35 a pharmaceutically acceptable salt thereof.


18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.

19. A process for preparing a compound of Formula I:




in which n, t, u, X, Y, Z, R¹, R² and R³ are as defined in claim 1 and the pharmaceutically acceptable salts and N-oxides thereof, which process comprises:

(a) alkylating a compound of Formula 2:




in which each X, Y, Z and R³ are as defined above with respect to Formula I, with a compound of Formula 3:




in which L is a leaving group, R⁶ and R⁷ form oxo or a carbonyl protective group and each n, t, u, R¹ and R² are as defined above with respect to Formula I, and deprotecting when necessary;

(b) acylating a compound of Formula 4:



5

in which each t , u , R^1 and R^2 are as defined above with respect to Formula I, with a compound of Formula 5:




10


in which L is a leaving group and each n , X , Y , Z and R^3 are as defined above with respect to Formula I;

(c) (1) alkylating 4-piperidone with a compound of Formula 3:

15




in which L is a leaving group, R^6 and R^7 form oxo or a carbonyl protective group and each n , t , u , R^1 and R^2 are as defined above with respect to Formula I, to give a compound of Formula 7:



and

(2) reacting the compound of Formula 7 with a cyanide salt and ammonium carbonate and deprotecting when necessary to give a compound of Formula I in which R^3 is hydro;


(d) (1) reacting a compound of Formula 7:



10

in which R^6 and R^7 are form oxo or a carbonyl protective group and each n , t , u , R^1 and R^2 are as defined above with respect to Formula I, with a cyanide salt and sodium bisulfate to give a corresponding compound of Formula 9:


15



and


(2) reacting the compound of Formula 9 with chlorosulfonyl isocyanate and deprotecting when necessary to give a compound of Formula I in which R^3 is hydro;

(e) (1) reacting a compound of Formula 7:




25

in which R⁶ and R⁷ form oxo or a carbonyl protective group and each n, t, u, R¹, and R² are as defined above with respect to Formula I, with trimethylsulfoxonium iodide to give a
 5 corresponding compound of Formula 12:



12

(2) aminating the compound of Formula 12 with an amine
 10 of the Formula NHR³ to give a corresponding compound of Formula 17:




17

15 and

(3) reacting the compound of Formula 11 with 1,1'-carbonyldiimidazole or 1,1'-thiocarbonyldiimidazole and deprotecting when necessary to give a compound of Formula I in which Z is C(O) or C(S), respectively;

20


(f) (1) reacting a compound of Formula 7:



7

in which R^6 and R^7 form oxo or a carbonyl protective group and each n , t , u , R^1 and R^2 are as defined above with respect to Formula I, with a cyanide salt and an ammonium salt to give a corresponding compound of Formula 14:

5




14

(2) reacting the compound of Formula 14 with carbon oxysulfide or carbon disulfide and deprotecting when necessary to give a compound of Formula I in which Z is $C(O)$ or $C(S)$, respectively, and R^3 is hydro;

10

(g) (1) hydrolyzing a compound of Formula 14:




15

14

in which R^6 and R^7 form oxo or a carbonyl protective group and each n , t , u , R^1 and R^2 are as defined above with respect to Formula I, to give a corresponding compound of Formula 18:

20



18

(2) reacting the compound of Formula 16 with 1,1'-carbonyldiimidazole or 1,1'-thiocarbonyldiimidazole to

give a compound of Formula I in which Z is C(O) or C(S), respectively, and R³ is hydro; and

(h) optionally further reducing a compound of Formula I in which R¹ is nitro to give a compound of Formula I in which R¹ is amino;

(i) optionally further reacting a compound of Formula I in which R¹ is amino with an isothiocyanate of the formula R⁵NCS, in which R⁵ is as defined above with respect to Formula I, to give a corresponding compound of Formula I in which R¹ is -NHC(S)NHR⁵;

(j) optionally further reacting a compound of Formula I in which R¹ is amino with an appropriate sulfonyl halide to give a compound of Formula I in which R¹ is -NHSO₂R⁵, wherein R⁵ is as defined above with respect to Formula I;

(k) optionally further reacting a compound of Formula I in which R¹ is amino with an appropriate sulfonyl halide to give a compound of formula I in which R¹ is -NHSO₂R⁵, wherein R⁵ is as defined above with respect to Formula I,

(l) optionally further alkylating a compound of Formula I in which R³ is hydro with a suitable alkylating agent to give a compound of Formula I in which R³ is as defined above with respect to Formula I;

(m) de-alkylating a compound of Formula I in which R³ is (C₁₋₆)alkyl to give a compound of Formula I in which R³ is hydro;


(n) optionally further oxidizing a compound of Formula I to give an N-oxide derivative thereof;

(o) optionally further reducing an N-oxide derivative of a compound of Formula I to unoxidized form;

(p) optionally further converting a compound of Formula I
5 into a pharmaceutically acceptable salt; and

(q) optionally further converting a salt form of a compound of Formula I to non-salt form.

10 20. A compound of Formula 3(a):



3(a)

in which:

- 15 n is 2, 3, 4, 5 or 6;
t is 1, 2, 3 or 4 and u is 0 or 1 (provided that t is not 1 when u is 0);
L is a leaving group;
R¹ is independently amino, aryloxy, aryl(C₁₋₄)alkyloxy,
20 arylsulfonyl, arylthio, carbamoyl, cyano, halo, nitro, thiocarbamoyl, thioureido, ureido, a group selected from (C₁₋₄)alkyl, (C₁₋₄)alkyloxy and (C₁₋₄)alkylthio (optionally further substituted with one to three halo atoms), a group selected from -NHSO₂R⁵, -NHC(O)R⁵,
25 -NHC(O)NHR⁵, -NHC(S)NHR⁵ and -SO₂NHR⁵ (which R⁵ is (C₁₋₄)alkyl (optionally further substituted with one to three halo atoms) or a group selected from aryl, aryl(C₁₋₄)alkyl, heteroaryl and heteroaryl(C₁₋₄)alkyl (optionally further substituted with one to two
30 radicals independently selected from amino, carbamoyl, cyano, halo, nitro, a group selected from (C₁₋₄)-

alkanoyl, (C₁₋₄)alkylsulfonylamino, (C₁₋₄)alkanoyl-amino, (C₁₋₄)alkyl and (C₁₋₄)alkyloxy, optionally further substituted with one to three halo atoms, and a group selected from aryl, arylsulfonyl, heteroaryl and heteroarylsulfonyl, optionally further substituted with one to two radicals independently selected from amino, cyano, halo, nitro and a group selected from (C₁₋₄)alkyl and (C₁₋₄)alkyloxy, optionally further substituted with one to three halo atoms)) or with an adjacent R¹ radical form ethylenedioxy, methylenedioxy or butadienylene (which butadienylene is optionally further substituted with one to two radicals selected from halo and (C₁₋₄)alkyloxy); and R² is hydroxy, halo, (C₁₋₄)alkyloxy or aryl(C₁₋₄)alkyloxy; and the pharmaceutically acceptable salts and N-oxides thereof.

21. A compound according to any one of claims 1-17 insofar as it is manufactured by the process according to claim 19 or a process equivalent thereto.

22. A compound according to any one of claims 1-17 for use as therapeutically active substance, especially for treating diseases which can be ameliorated by blocking 5-HT_{2C} receptors.

23. The use of compounds according to any one of claims 1-17 for treating diseases which can be ameliorated by blocking 5-HT_{2C} receptor for the production of medicaments containing them.

24. The invention as hereinbefore described.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/02554

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D471/10 C07D498/10 A61K31/435 C07D317/14
 //(C07D471/10,235:00,221:00),(C07D498/10,263:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE,A,18 15 450 (SCIENCE-UNION) 4 September 1969 see page 4, paragraph 4 - page 5, paragraph 1; claim 1 ---	1,18
X	CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 26, no. 8, 1978, TOKYO JP, pages 2502-2507, XP002013868 KIUTO SASAJIMA ET AL.: "Synthetic studies on psychotropic agents. I. A new synthesis of 2'-amino-4'-fluorobutyriphenone derivatives using a selective ortho-amination of 2',4'-difluorobutyrophenone derivatives" see compound IV ---	20
X	EP,A,0 450 995 (JOUVEINAL) 9 October 1991 see page 22, line 1 - line 12 -----	20

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "&" document member of the same patent family

Date of the actual completion of the international search

20 September 1996

Date of mailing of the international search report

27.09.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 96/ 02554

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 23 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/02554

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A-1815450	04-09-69	BE-A- 725565	16-06-69
		CH-A- 500224	15-12-70
		FR-M- 348	29-03-71
		FR-E- 96352	16-06-72
		GB-A- 1193700	03-06-70
		SE-B- 343585	13-03-72
		US-A- 3594386	20-07-71

EP-A-450995	09-10-91	FR-A- 2658821	30-08-91
		AT-T- 106881	15-06-94
		AU-B- 632398	24-12-92
		AU-A- 7134191	29-08-91
		CA-A- 2037084	29-08-91
		DE-D- 69102335	14-07-94
		JP-A- 5320103	03-12-93
		US-A- 5143938	01-09-92
		US-A- 5236947	17-08-93
